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Studies on the mechanisms and consequences of drug-induced perturbations of lysosomal structure and 
function 
Randall Louis Logan 
The University of Kansas, 2013 
From a clinical perspective, a drug’s pharmacokinetic properties (e.g., the volume of distribution, 
clearance, and half-life) are vitally important as these parameters are used to establish the proper 
dosing regimen necessary to achieve a desired drug exposure.  Failure to properly account for changes 
to a drug’s expected pharmacokinetic properties, whether perpetrated by pharmacological insult (drug-
drug interaction) or a disease state, can result in an improper dosing regimen that either fails to achieve 
therapeutic drug levels or, conversely, can result in drug levels that reach toxic concentrations.  
Identifying conditions that can alter the expected pharmacokinetic properties of drugs is therefore 
immensely important.  Previous work in our lab has shown that lysosomotropic drugs, i.e., drugs that 
preferentially accumulate within lysosomes due to an ion trapping-type mechanism, cause a marked 
expansion in the volume of lysosomes which can result in a drug-drug interaction involving lysosomes.  
Although this novel drug-drug interaction was well characterized the mechanistic basis explaining how it 
developed was not established.  Within this work we have explored the cellular mechanisms underlying 
the development of the drug-induced expansion in lysosomal volume and the ensuing drug-drug 
interaction.  Our data shows that the drug-induced expansion in lysosomal volume is achieved through a 
combination of reduced vesicle-mediated trafficking out of the lysosomes, the induction of autophagy, 
and the activation of lysosome biogenesis.  We have additionally explored a structure activity 
relationship which implicates a drug’s amphiphilicity and lysosomotropic properties as important 
features that correlate with their propensity to induce an expansion in lysosomal volume.  Overall, the 
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data presented in this work can be used to help explain the sources of variability seen in the 
pharmacokinetic properties of lysosomotropic drugs. 
In parallel to these studies we have also explored potential treatment strategies that can reduce the 
bloated lysosomal volume seen in cells with dysfunctional lysosomes.  Using two cell models that exhibit 
dysfunctional lysosomes (lysosomotropic drug-treated cells or lysosomal storage diseased cells), we 
have examined how vitamin E helps to recover lysosomal volume.  Our data indicates that vitamin E 
reduces both ion trapping-dependent (aqueous volume of lysosomes) and ion trapping-independent 
(lipid binding) drug accumulation mechanisms within cells.  To our knowledge, this is the first report 
detailing that vitamin E reduces the aqueous volume of lysosomes.  This finding is important as it helps 
to more fully explain how vitamin E is eliciting its positive effects within cells.  Additionally, we have also 
examined a structure activity relationship of vitamin E and its ability to reduce lysosomal volume.  Our 
data indicates that the physical structure of vitamin E, rather than its antioxidant properties, is the 
primary feature of vitamin E that correlates with its ability to reduce the bloated lysosomal volume seen 
in cells with dysfunctional lysosomes.  Overall, this data can be used as a foundation to stage additional 
studies that could ultimately lead to the development of more potent and better drug-like molecules 
that could be used to treat lysosomal storage diseases and the toxic effects of lysosomotropic drug-
treatments. 
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Chapter 1. Introduction 
Statement of the Problem 
Lysosomes are dynamic organelles that have a centralized role in maintaining normal catabolic and 
conversionary processes of lipids, proteins, nucleic acids, and carbohydrates in virtually all human cells.  
Many vital cellular components are also transited through this organelle leading lysosomes to be one of 
the main trafficking hubs within cells (Gahl 1989).  Dysfunction of normal lysosome activity, whether 
perpetrated by pharmacological insult or genetic mutation, can have profound effects on cellular 
physiology which can result in enlarged lysosomes, phospholipidosis, induction of autophagy, and overt 
cytotoxicity.  Many publications have detailed the impact of these effects in that they can create a 
distribution-based drug-drug interaction (Funk and Krise 2012, Logan, Funk et al. 2012), alter drug 
activity and toxicity (Ndolo, Forrest et al. 2010, Ndolo, Jacobs et al. 2010), alter the efficiency of virus 
entry and replication (Levine and Kroemer 2008, Kudchodkar and Levine 2009), and alter the clearance 
of aggregation prone proteins such as mutated huntingtin, α-synuclein, and ß-amyloid which are 
associated with Huntington’s, Parkinson’s, and Alzheimer’s disease, respectively (Rubinsztein 2006, 
Madeo, Eisenberg et al. 2009).  A large number of currently approved drugs are lysosomotropic which 
means that they possess physicochemical properties that make them substrates for lysosomal 
sequestration by an ion-trapping type mechanism.  Many of these drugs can cause lysosomal 
dysfunction which can ultimately give rise to some of the observed cellular effects previously 
mentioned.  Although a direct cause and effect relationship is currently not well established between 
drug-induced lysosomal changes (namely phospholipidosis) and cytotoxicity, these drugs nonetheless 
can trigger the FDA to request additional biochemical and toxicological studies to prove the safety of 
drug candidates prior to FDA approval.  For this reason, drug-induced perturbations of lysosome 
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structure and function are becoming recognized as an important consideration in the drug development 
process (Reasor, Hastings et al. 2006, Tengstrand, Miwa et al. 2010).  A more complete understanding of 
the mechanisms underlying these drug-induced changes to lysosomes and their ultimate impact on in 
vitro and in vivo pharmacokinetics could therefore be highly valuable from a pharmacological 
perspective.  In this work we have sought to characterize the drug-induced changes to lysosomes that 
arise after treating cells with lysosomotropic drugs.  We have specifically analyzed the molecular and 
cellular mechanisms underlying these effects and have detailed the potential clinical ramifications of 
these changes. 
Lysosomes and the accompanying protein machinery are also recognized as being a “genetic-mutation 
hotspot” in that a large number of neurodegenerative diseases, collectively referred to as lysosomal 
storage diseases (LSD), can arise from functional mutations in these lysosome-associated proteins (Table 
1.1) (Jeyakumar, Dwek et al. 2005).  Interestingly, some lysosomotropic drugs are capable of inducing a 
cellular phenotype similar to that seen in lysosomal storage diseased cells.  These similarities include an 
expanded lysosomal volume (Karageorgos, Isaac et al. 1997, Kolter and Sandhoff 2010, Xu, Liu et al. 
2012), an impaired rate of vesicle-mediated lysosomal egress (Goldman, Funk et al. 2009), and the 
hyper-accumulation of lipids resulting in the formation of membrane whorls (lipid-laden lysosomes) 
(Jeyakumar, Dwek et al. 2005).  Many LSDs cause progressive neurodegeneration and can ultimately 
lead to death.  To date, there are limited options for treating LSDs.  These treatment regimens include 
substrate limitation/depletion, enzyme replacement therapy, or the use of cyclodextrins (Desnick, 
Thorpe et al. 1976, Grabowski and Hopkin 2003, Mehta 2008, Liu, Turley et al. 2009).  There is, 
therefore, a demand for additional therapies that might be used to treat these diseases.  With this in 
mind, we have also sought to develop and characterize in vitro treatment strategies that can help to 
recover lysosome function in these diseased cells.  Ultimately we hope that these treatment strategies 
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will provide the foundation necessary to catalyze the development of novel treatment options for 
patients harboring a lysosomal storage disease. 
Objectives of this work 
In this work we have sought to characterize how weakly basic drugs change lysosome form and function 
in cultured human cells.  We have identified several of the physiological processes underlying the 
mechanistic basis for the expanded lysosomal volume phenotype seen in cells treated with 
lysosomotropic drugs.  We have also provided evidence depicting how these drug-induced changes to 
lysosomes influence drug accumulation and detailed the impact that these changes might have on 
whole body pharmacokinetics.  In addition, we have evaluated the structure activity relationship of 
weakly basic drugs and correlated certain physicochemical properties of these drugs with their 
propensity to induce changes to lysosomes. 
In parallel to the work exploring the basis for the drug-induced expansion in lysosomal volume we have 
also sought to develop treatment strategies for recovering a normal lysosome phenotype.  Using the 
two cellular models that exhibit an expanded steady state lysosomal volume (lysosomotropic drug-
treated and lysosomal storage diseased cells), we have evaluated the ability of vitamin E and many 
amphiphilic phenols to restore lysosome function and thereby reduce the expanded lysosomal volume.  
We have also laid the foundation for a structure activity relationship for vitamin E and its ability to 
restore lysosome function. 
Introduction 
Many drugs that are currently approved for human use possess physiochemical properties that cause 
them to be lysosomotropic, meaning that they are substrates for lysosomal sequestration.  Lysosomal 
sequestration of weakly basic drugs occurs due to an ion-trapping type mechanism which is governed by 
three major parameters: the large pH gradient existing between the lumen of the lysosome and the 
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cytosolic and extracellular space, the basicity of the molecule (pKa), and the membrane permeability of 
the ionized species of the weak base (alpha value) (de Duve, de Barsy et al. 1974). 
Lysosomal sequestration can cause significant changes to the intracellular disposition and total cellular 
accumulation of a drug.  These effects can have significant clinical considerations as they can alter drug 
activity, influence toxicity, and alter whole body pharmacokinetic parameters (Obach, Lombardo et al. 
2008, Ndolo, Forrest et al. 2010, Ndolo, Jacobs et al. 2010, Funk and Krise 2012, Ndolo, Luan et al. 2012).  
Much of the previous work in our lab has focused on relating how relatively small changes in lysosomal 
sequestration can lead to dramatic effects on the activity and toxicity of weakly basic drugs.  Using in 
vitro and in vivo assays Ndolo et al. showed that the activity of weakly basic anticancer drugs can be 
significantly altered by either tuning the pKa of the drug or by modulating the pH of the lysosomal 
lumen, both of which lead to altered degrees of drug entrapment in the lysosomes. 
Lysosomal sequestration can also impart significant changes to a drug’s whole body pharmacokinetic 
parameters specifically the volume of distribution and half-life.  Obach and Coworkers have illustrated 
this relationship by evaluating the pharmacokinetic properties of over 600 currently approved 
pharmaceutical drugs and showed that weakly basic drugs tend to possess a significantly larger volume 
of distribution and half-life versus acid, neutral, or zwitterionic drugs (Obach, Lombardo et al. 2008).  A 
classic example of this relationship can be seen by comparing the pharmacokinetic properties of two 
structurally similar macrolide antibiotics, erythromycin and azithromycin (Figure 1.1).  Due to the 
additional weakly basic functional group azithromycin theoretically has an enhanced lysosomal 
sequestration capacity versus its monobasic counterpart erythromycin.  The enhanced lysosomal 
sequestration of azithromycin translates into an increased cellular accumulation in peripheral tissues 
which ultimately leads to a substantial increase in the volume of distribution and half-life of 
azithromycin (Figure 1.1). 
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These examples help to illustrate the relationship between a drug’s lysosomal sequestration capacity 
and its activity, toxicity, and pharmacokinetic properties.  With this in mind, Funk and Krise have 
recently detailed an interesting phenomenon whereby lysosomotropic drugs were capable of increasing 
the lysosomal sequestration capacity of cultured human cells (Figure 1.2), a condition hereby referred to 
as the expanded lysosomal volume phenotype (expanded LVP) (Funk and Krise 2012).  In these studies 
they found that this phenomenon was achieved at clinically relevant concentrations, i.e., at media 
concentrations of drug that are similar to those observed in the tissues of organisms treated under 
normal dosing regimens.  For example, the weakly basic drugs amitriptyline, imipramine, and quinacrine 
accumulate in the brain of mice and rats up to low micromolar concentrations (Glotzbach and Preskorn 
1982, Yung, Huang et al. 2004, Shargel, Wu-Pong et al. 2005) which is comparable to the low micromolar 
concentrations evaluated by Funk and Krise.  This implies that the drug-induced increase to the 
lysosomal sequestration capacity of cells is a phenomenon that can be expected to occur under normal 
dosing regimens of weakly basic drugs. 
Funk and Krise further postulated that the drug-induced increase to the lysosomal sequestration 
capacity of cells could result in a drug-drug interaction involving lysosomes.  In this drug-drug interaction 
pathway the lysosomotropic drug that induced the expanded LVP was considered the perpetrator drug 
as it potentiated an increase to the cellular accumulation of secondarily administered lysosomotropic 
drugs i.e., the victim drug.  We propose that these findings potentially have a broad application in 
explaining some of the variability seen in the pharmacokinetic properties of lysosomotropic drugs.  By 
virtue of their extensive accumulation in the lysosomes of peripheral tissues, lysosomotropic drugs tend 
to have a very large volume of distribution and half-life that are accompanied with significant inter- and 
intra-patient variability.  For example, the antiarrhythmic drug amiodarone has a reported steady state 
volume of distribution ranging from 40 L/kg to 84 L/kg and a terminal half-life ranging from 20 days to 
47 days (Chow 1996).  The inability to accurately account for changes in a drug’s pharmacokinetic 
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properties could ultimately result in a dosing regimen that either fails to reach therapeutic drug levels 
or, conversely, rises to toxic drug levels. 
Motivated by the potential clinical ramifications of this phenomenon, we have sought to define the 
mechanisms underlying the development of the expanded LVP caused by lysosomotropic drugs.  We 
have identified two physiological processes that likely contribute to the expanded LVP and detailed how 
these processes can contribute to a drug-drug interaction involving lysosomes.  In an effort to advance 
our understanding of how these lysosomotropic drugs are interacting with lysosomes on a molecular 
level we have also reported a structure activity relationship detailing the physiochemical properties of 
lysosomotropic molecules that correlate with their potency in inducing the expanded LVP.  Overall, the 
information presented in this work will help to elucidate the mechanisms underlying the development 
of the expanded LVP and the ensuing drug-drug interaction involving lysosomes. 
Lysosomes and lysosomal storage diseases 
Lysosomes have often been described as the stomach of the cell owing to their functional role in 
performing many of the cell’s catabolic activities.  Although this simplistic description is fairly accurate it 
gives the impression that lysosomes are simplistic as well.  In reality, lysosomes are a highly dynamic 
organelle that can adapt and change to different cellular stresses.  Many important cellular pathways 
converge at the lysosome leading lysosomes to be one of the main trafficking hubs within cells.  These 
pathways/processes include the endocytic pathway, the biosynthetic pathway, autophagy, phagocytosis, 
and antigen-processing and loading in antigen presenting cells (APCs) (Kornfeld and Mellman 1989, 
Luzio, Poupon et al. 2003, Hsing and Rudensky 2005, Saftig and Klumperman 2009).  Although this list is 
not all encompassing it is intended to illustrate the point that lysosomes are involved in a diverse set of 
cellular functions.  Lysosomes do however perform a common function for all of these cellular pathways, 
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which is enzymatic degradation and trafficking.  It therefore should not be surprising to discover that 
cells are highly sensitive to gross changes in the catabolic activity of lysosomes.   
Lysosomal storage diseases (LSD)s are a set of inheritable diseases that arise as a result of impaired 
catabolic activity of lysosomes.  These diseases collectively present in the human population at 1 in 
8,000 live births.  There are currently over 40 documented LSDs arising from mutations in one of the 50-
60 soluble hydrolases present within lysosomes.  A common feature among these diseases is the buildup 
of undegraded material within the lysosomal system such as sphingolipids, glycosaminoglycans, or 
cholesterol (Jeyakumar, Dwek et al. 2005).  Although these materials are normal endogenous molecules, 
the lysosomal system is incapable of sustaining its normal function in the presence of such a massive 
constipation of substrate.  An exact mechanistic understanding of how this substrate-
hyperaccumulation affects downstream processes is currently unknown.  However, common among 
these diseases is the presentation of brain pathologies.  LSDs typically present in the early stages of life 
with a progressive neurodegeneration that can ultimately lead to death (Futerman and van Meer 2004, 
Jeyakumar, Dwek et al. 2005).  Patients harboring these LSDs are unfortunately limited to a small 
number of treatment options including substrate limitation/depletion, enzyme replacement therapy, or 
the use of cyclodextrins (currently not approved by the FDA as a treatment in the USA) (Desnick, Thorpe 
et al. 1976, Grabowski and Hopkin 2003, Mehta 2008, Liu, Turley et al. 2009).  LSDs therefore represent 
an underserved set of diseases regarding available pharmaceutical interventions. 
Ion Trapping-Type Mechanism 
The way in which weakly basic molecules become entrapped within lysosomes is due to an ion trapping-
type mechanism (also referred to as pH partitioning, lysosomal entrapment, or lysosomal sequestration) 
(de Duve, de Barsy et al. 1974).  This mechanism is largely governed by the physicochemical properties 
of the weakly basic molecule and the properties of the cellular environment.   
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Substrates for an ion trapping-type mechanism (also refered to as lysosomotropic molecules) possess 
two main physicochemical properties.  Firstly, they contain a weakly basic amine with an acid 
dissociation constant (pKa) of approximately 6 to 7 or higher (Trapp, Rosania et al. 2008, Ndolo, Luan et 
al. 2012).  Secondly, substrates for ion trapping also exhibit relatively high membrane permeabilities 
while existing in their unionized (uncharged) form but are relatively membrane impermeable while in 
their ionized (charged) form.  This differential membrane permeability is referred to as the α-value and 
is derived from the ratio between the intrinsic partition coefficient of the ionized versus the unionized 
forms of the molecule (Duvvuri, Gong et al. 2004). 
The properties of the cellular environment also play an important role in the mechanism of ion trapping.  
The pH of three membrane-isolated compartments, i.e., the extracellular space, the cell cytosol, and the 
lysosomal lumen, are the primary drivers of this mechanism.  The pH of the extracellular space and the 
cell cytosol are relatively neutral with a pH of approximately 7, while the lysosomal lumen is sustained at 
a much more acidic pH of approximately 4.0 - 4.5 (Ndolo, Jacobs et al. 2010, Ndolo, Luan et al. 2012). 
Figure 1.3 illustrates a cartoon representation of the ion trapping mechanism.  In the neutral pH of the 
extracellular and cytosolic space weakly basic molecules exist in equilibrium between their ionized (BH+) 
and unionized form (B).  Substrates for ion trapping exhibit a high degree of membrane permeability in 
their unionized form (B) and are considered to freely partition across all lipid bilayers of the cell.  When 
a weakly basic molecule partitions into the lumen of the lysosome the equilibrium balance of the 
molecule shifts due to the significantly more acidic enviornment.  The vast majority of the weakly basic 
molecule therefore exists in its ionized form (BH+).  Due to the low degree of membrane permeability of 
the ionized form of these molecules they are thereby trapped within the acidic lysosomal lumen. 
The ion trapping mechanism plays a central role in many of the topics explored within this work.  
Frequently discussed is the impact that the lysosomal pH gradient, i.e., the difference in pH between the 
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lysosomal lumen versus the cell cytosol and extracellular space, has on the accumulation of weakly basic 
drugs.  Conditions that dissipate the lysosomal pH gradient, i.e., alkalinize the lyososmal pH, can cause a 
significant decrease in the lysosomal entrapment of weakly basic molecules (Bawolak, Morissette et al. 
2010, Logan, Funk et al. 2012, Ndolo, Luan et al. 2012).  If the pH of the lysosomal lumen is brought to 
the same pH as the cell cytosol then, theoretically, no ion trapping would occur.  Throughout this work 
nigericine and monensin are used as a tool to alkalinize the lysosomes.  These two molecules are 
considered to be ionophores as they are capable of carrying H+ ions across lipid membranes which 
ultimately results in the dissipation of the lysosomal pH gradient (Nakazato and Hatano 1991, 
Prabhananda and Ugrankar 1991).    
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Table 1.1  The table shows selected examples of lysosomal storage disorders classified according to 
molecular defect. Modified, with permission, from REK 5 © (2004) Oxford University Press 
(Origninally pubished in: Nat Rev Neurosci 6(9): 713-725.)  
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Figure 1.1  Two structurally similar macrolide antibiotics erythromycin and azithromycin and their 
reported volume of distribution (Vd) and half-life (t1/2) in humans (package inserts, Journal of 
Pharmaceutical Sciences 67;8 1057-1059 (1978), Antibiotics Chemother. 25, 181-203 (1978), Clinical 
Therapeutics 18;1 56-72 (1996), Infect Dis Clin N Am 18, 621-649 (2004))  
Erythromycin Azithromycin
Vd = 2 L/kg
t½ = 1-4 hr
Vd = 100 L/kg
t½ = 40-68 hr
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Figure 1.2  LTR accumulation in MDA-1986 cells following a 24 h treatment with vehicle alone or various 
CADs at a concentration of 10 μM. Cellular accumulation of LTR as a percentage of vehicle-treated 
control cells is represented as mean ± SD from three independent experimental evaluations (***, p < 
0.001 by Student’s t test). 
Published in: Ryan S. Funk; Jeffrey P. Krise; Mol. Pharmaceutics  2012, 9, 1384-1395. 
DOI: 10.1021/mp200641e 
Copyright © 2012 American Chemical Society 
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Figure 1.3  Lysosomal sequestration of weakly basic molecules occurs by an ion trapping-type 
mechanism.  The figure represents a single cell.  The dotted line signifies the plasma membrane of the 
cell while the solid line represents the lysosomal membrane.  In the neutral pH of the extracellular and 
cytosolic space weakly basic molecules exist in equilibrium between their ionized (BH+) and unionized 
form (B).  Substrates for ion trapping exhibit a high degree of membrane permeability in their unionized 
form (B) and are considered to freely partition across all lipid bilayers of the cell.  When a weakly basic 
molecule partitions into the lumen of the lysosome the equilibrium balance of the molecule shifts due to 
the significantly more acidic environment (pH ~4).  The vast majority of the weakly basic molecule 
therefore exists in its ionized form (BH+).  Due to the low degree of membrane permeability of the 
ionized form of these molecules they are thereby trapped within the acidic lysosomal lumen.  
cytosol
(~pH 7)
B
BH+
B
BH+
lysosome
(~pH 4)
BH+
BH+
BH+
B
BH+
extracellular
space
(~pH 7)
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Chapter 2. The role of autophagy and lysosomal trafficking defects on the development of a drug-drug 
interaction involving lysosomes 
Introduction 
Many drugs that are currently approved for human use possess physiochemical properties that cause 
them to be substrates for lysosomal sequestration.  Lysosomal sequestration of weakly basic drugs 
occurs due to an ion-trapping type mechanism which is governed by three major parameters: the large 
pH gradient existing between the lumen of the lysosome and the cytosol and extracellular space, the 
basicity of the small molecule (pKa), and the membrane permeability of the ionized species of the weak 
base (alpha value) (de Duve, de Barsy et al. 1974).  In addition to these parameters the total volume of 
the lysosomal system can also influence the lysosomal sequestration capacity of a cell.  Conditions that 
lead to changes in the steady state volume of the lysosomes can therefore lead to changes in a cell’s 
capacity to accumulate lysosomotropic drugs.  This can lead to changes in the degree of drug 
accumulation in peripheral tissues and ultimately affect a drug’s pharmacokinetic properties, specifically 
the volume of distribution and half-life.   
From a clinical perspective understanding and predicting changes to the pharmacokinetic properties of a 
drug is vitally important as these properties are used to establish the proper dosing regimen prescribed 
to patients.  The inability to properly account for changes in a drug’s pharmacokinetic properties could 
result in dosing regimens that either fail to reach therapeutic drug levels or, conversely, reach drug 
levels that are too high and become cytotoxic.  With this in mind, a greater understanding of conditions 
or mechanisms by which the pharmacokinetic properties of a drug can change would be highly valuable. 
Lysosomotropic drugs are unique in that they typically have an extremely large volume of distribution 
and half-life but these parameters can also exhibit extremely large variability.  For example, the 
lysosomotropic drug amiodarone has been reported to have a steady state volume of distribution 
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ranging from 40 L/kg to 84 L/kg and a terminal half-life ranging from 20 days to 47 days (Chow 1996).  
Keeping in mind that changes in the steady state volume of lysosomes could translate into changes in 
the volume of distribution and half-life of these lysosomotropic drugs, we have focused on evaluating 
the potential influence that autophagy might have in altering lysosomal volume.  Ultimately, this could 
be used to explain why lysosomotropic drugs, such as amiodarone, are exhibiting such a large variability 
in their volume of distribution and half-life. 
Funk and Krise previously reported that many lysosomotropic drugs were capable of perpetrating an 
intracellular distribution based drug-drug interaction which was mediated by an expansion in the steady 
state volume of the lysosomes (Funk and Krise 2012).  Although this phenomenon was well described, 
the mechanistic basis for this phenomenon was not determined.  In this chapter we explore the cellular 
mechanisms that are involved in causing an increase in the steady state volume of lysosomes seen in 
cells treated with these lysosomotropic drugs.  We have specifically focused on how autophagy, a 
normal physiological process involved in the clearance of long-lived proteins and dysfunctional 
organelles (Levine and Kroemer 2008), can influence the steady state volume of lysosomes.  We then 
explored the potential involvement of autophagy as a physiological process that contributes to the 
expanded lysosomal volume phenotype (expanded LVP) seen in cells treated with these perpetrator 
drugs.  We also detailed the impact that these lysosomotropic drugs have on vesicle mediated trafficking 
out of the lysosomes.  We further explored how the changes to the steady state volume of lysosomes 
caused by autophagy and the expanded LVP can lead to a drug-drug interaction involving lysosomes. 
Materials and Methods 
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Cell Lines and Reagents 
Wild-type (WT) human fibroblasts (catalogue # CRL-2076) were purchased from ATCC (Manassas, VA).  
All cells were cultured in glutamine-free DMEM supplemented with 10% FBS, 10mM HEPES, 1mM 
Sodium Pyruvate, and 2mM Glutamax and maintained at 37 degrees C and 5% CO 2.  Cells were 
routinely subcultured to maintain 50% to 90% confluency.  Experiments were carried out within 10 
passages following removal from cryopreservation. Dulbecco’s phosphate buffered saline (D-PBS), 
Dulbecco’s modified Eagle’s medium (DMEM), HEPES, sodium pyruvate, glutamax, and LysoTracker Red 
DND-99 (LTR) were purchased from Invitrogen (Carlsbad, CA).  Fetal bovine serum (FBS) was purchased 
from Atlanta Biologicals (Lawrenceville, GA).  Carbamazepine, rapamycin, valproic acid, halofantrine, 
propranolol, U18666A, lidocaine, imipramine, haloperidol, chloroquine, bupivacaine, quinacrine, 
Laemmli buffer, and sodium deoxycholate were purchased from Sigma-Aldrich (St. Louis, MO).  (S)-
naproxen was purchased from Cayman Chemical Company (Ann Arbor, MI).  Pierce BCA protein assay kit 
was ordered from ThermoScientific (Rockford, IL).  Anti-LCB3I/II antibody (catalogue # ab51520) was 
purchased from AbCam (Cambridge, United Kingdom).  Anti-beta actin antibody (catalogue #8H10D10) 
was purchased from Cell Signaling Technology (Danvers, MA).  3[H]-dextran 70,000 MW, 3[H]-
halofantrine, and 3[H]-propranolol were purchased from American Radiolabeled Chemicals, Inc. (St. 
Louis, MO).   
LysoTracker Red accumulation assay 
WT human fibroblasts were grown in plastic 12-well culture plates (Corning Life Sciences) at a seeding 
density of approximately 75,000 cells per well.  Following a 48-hour pretreatment with various drugs 
(concentrations for each drug is stated in the figure legend), LysoTracker Red was spiked into the growth 
media to a concentration of 200nM and the cells were incubated for 1 hour.  Cells were then rapidly 
washed twice with 4 degrees C D-PBS.  Cells were lysed with lysis buffer (50 mM tris base, 150 mM NaCl, 
1% NP40, pH 7.4).  The quantity of LTR was determined by fluorescent signal in relative fluorescence 
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units (RFU) using a Bio-Tek FL600 microplate fluorescence reader.  Protein abundance was measured for 
each sample using the BCA method.  Measured LTR signal (RFU) was then normalized to protein.  These 
normalized values were then compared to the control condition (vehicle treated) and depicted as a 
percentage of the control.   
Drug Accumulation Assays 
Following a 48-hour pretreatment with rapamycin (200nM) or vehicle alone, cells were exposed to 
propranolol or halofantrine for 1 hour.  Naproxen accumulation (5μM) was conducted concurrently with 
the pretreatment of rapamycin (200nM) or vehicle alone for 48 hours.  The concentrations chosen for 
these compounds (200nM propranolol, 200nM halofantrine, 5uM naproxen) were determined as the 
necessary concentrations to yield adequate signal while also being incapable of inducing a lysosomal 
volume expansion.  Cells were then washed twice with 4 degrees C D-PBS rapidly to prevent diffusion of 
cell-associated drug.  The cells were then lysed using lysis buffer (50 mM tris base, 150 mM NaCl, 1% 
NP40, pH 7.4).  The quantity of tritium-labeled drug (propranolol and halofantrine) was measured in 
disintegrations  per minute (DPM) using a Beckman LS 60001C liquid scintillation counter, and naproxen 
was measured by LC-MS/MS using the method stated in LC-MS/MS quantification of naproxen .  
Background signal contributed from non-specific binding to the plate surface was subtracted from each 
measurement.  Protein abundance was measured for each sample using the BCA method.  All measured 
quantities of drug accumulation were then normalized to protein.  These normalized values were then 
compared to the corresponding control condition (vehicle treated) and depicted as a percentage of the 
control.   
LC-MS/MS quantification of naproxen 
To measure naproxen cellular accumulation, a drug extraction was performed to recover naproxen  from 
the cell lysate using the following technique.  Methyl tert-butyl ether was combined with the cell lysates 
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in a 5:1 ratio (v/v), respectively.  The samples were vortexed for 10 minutes and then centrifuged at 
15,000g for 10 minutes.  The top 95% of the supernatant was removed and the process was repeated.  
The supernatant was evaporated and the remaining solid particulates were then reconstituted in mobile 
phase prior to injection.  An integrated Agilent 1100 series liquid chromatography system with an API 
2000 (Applied Biosciences) triple quadrupole mass spectrometer was employed to quantitate drug 
extracted from cell lysates.  Liquid chromatography was conducted on an Agilent Zorbax Eclipse XDB- 
C18 column (2.1 x 150 mm 3.5µm particle size) (Santa Clara, CA).  All samples were analyzed with an 8 
µL sample injection.  Mobile phase A consisted of 10 mM ammonium acetate at pH 8.0.  Mobile phase B 
consisted of ACN.  Using 150 µL/min flow rate, the first minute of elution was an isocratic mixture of 
82% A followed by a linear gradient to 5% A for 3 minutes.  A linear gradient was then executed to 82% 
A over 0.5 minutes and maintained at 82% A for an additional 3.5 minutes.  The first 1.8 minutes of 
eluted sample was diverted to waste in order to avoid non-volatile material from entering the mass 
spectrometer. The mass spectrometer was equipped with an atmospheric ionization source and 
operated in the negative mode. Detection was by multiple reaction monitoring (MRM).   
Cell imaging 
All cell imaging was performed on a Nikon Eclipse 80i epifluorescence microscope equipped with a 60× 
(1.40 NA) oil immersion objective.  All images were acquired on a Hamamatsu ORCA ER digital camera.  
Images were analyzed using Metamorph software version 7.0 (Universal Imaging) and ImageJ software 
(free online atrsbweb.nih.gov) software. WT human fibroblasts were grown on glass coverslips under 
the stated growth conditions.  LTR was spiked into the growth media one hour prior to cell imaging.  The 
cells were then washed once quickly with 37 degrees C D-PBS.  The live cells were then rapidly imaged 
using the appropriate filter sets for LTR fluorescence.  Images were captured under identical instrument 
settings and scaled equally so that a direct comparison of fluorescence intensity and localization could 
be performed.   
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Western blot analysis 
WT human fibroblasts were grown in 100mm plastic Petri dishes (Corning Life Sciences)  at a seeding 
density of approximately 500,000 cells per dish.  Following a 48-hour treatment with various drugs 
(concentrations stated in figure legends) cells were washed twice with 4 degrees C D-PBS.  Cells were 
then lysed with RIPA buffer (150mM sodium chloride, 1% TX-100, 0.5% sodium deoxycholate, 0.1% SDS, 
50mM tris, pH 8.0, and the protease inhibitors APL & PMSF).  The protein abundance was then 
determined by the BCA method.  Protein samples were then mixed with Laemmli buffer.  All protein 
samples (25 µg per lane) were subjected to 12% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) for 120 minutes.  The proteins were then transferred to a 0.2 µm pore PVDF 
membrane (Millipore) using 300 V*hours.  The PVDF membrane was then exposed to primary antibody 
(1:4000 LC3B, 1:30,000 beta-actin) for two hours, washed, and then exposed to secondary antibody 
(1:4000  goat anti-rabbit HRP and goat anti-mouse HRP) for two hours.  Detection of HRP-conjugated 
antibody was achieved by chemiluminescence using Western Lightning-ECL (PerkinElmer) on 
autoradiograph film.   
Dextran release assay 
WT human fibroblasts were grown in plastic 6-well culture plates (Corning Life Sciences) at a seeding 
density of 175,000 cells per well.  Following a 48-hour treatment with various drugs or vehicle alone 
(concentrations stated in figure legends), the extracellular media was replaced with 1 mg/ml 70,000 MW 
dextran including 0.1 mg/mL tritium-labeled dextran also containing the indicated drug or vehicle alone.  
The cells were incubated for 6 hours in the presence of the dextran containing media.  Cells were then 
washed three times with 37 degrees C D-PBS.  The extracellular media was then replaced with dextran- 
free media containing the indicated drug or vehicle alone.  Following a 24-hour release period, the 
quantity of tritium-labeled dextran was measured in the extracellular media and in the cell lysates.  The 
cells were washed three times with 37 degrees C D-PBS and then lysed with lysis buffer (50 mM tris 
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base, 150 mM NaCl, 1% NP40, pH 7.4).  The quantity of tritium-labeled dextran was measured in 
disintegrations per minute (DPM) using a Beckman LS 60001C liquid scintillation counter.  Background 
signal contributed from non-specific binding to the plate surface was subtracted from each 
measurement.  The relative dextran release for each test condition was then compared to the control 
(vehicle treated) and depicted as a percentage of the control. 
Results and Discussion 
Lysosomotropic drugs are capable of inducing autophagy 
Funk and Krise previously identified a novel drug-drug interaction whereby one lysosomotropic drug 
could alter the cellular accumulation of a secondarily administered lysosomotropic drug.  In this work 
they discovered that these perpetrator drugs were causing an expanded lysosomal volume phenotype 
(expanded LVP).  They proposed that it was by virtue of this expanded lysosomal volume that the 
secondarily administered drug was achieving a greater cellular accumulation thereby resulting in a drug-
drug interaction.  Although several drugs were identified that could elicit this effect (Figure 1.2) the 
mechanistic basis for this phenomenon was not determined (Funk and Krise 2012).  In continuation of 
this work, we have sought to determine the cellular processes or conditions that might contribute 
membrane and material to lysosomes and thereby increase the steady state volume of the lysosomal 
system. 
The steady state volume of the lysosomes is achieved when the rate of input of membrane and material 
into the lysosomal system equals the rate of output of membrane and material from the lysosomal 
system.  There are several cellular processes or pathways that can deliver membrane and material to 
this system: the endocytic pathway, phatocytosis, the biosynthetic pathway, and the autophagic 
pathway (Figure 2.1) (Kornfeld and Mellman 1989, Luzio, Poupon et al. 2003).  Modulation of one 
pathway or a combination of them could foreseeably result in changes to the steady state volume of 
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lysosomes.  Using wild type human fibroblasts we first sought to isolate one of these input pathways, 
autophagy, and determine if the lysosomotropic perpetrator drugs were capable of modulating its 
normal homeostatic levels.  Under normal cell culture conditions the basal level of autophagy is 
relatively very low in Wild Type (WT) human fibroblasts.  We therefore hypothesized that if these 
perpetrator drugs influenced autophagy we should see a concomitant increase or induction of 
autophagy in the drug-treated cells. 
Prior to evaluating the potential involvement of autophagy in the development of the expanded LVP we 
first had to rationally choose an appropriate perpetrator drug concentration and exposure time.  With 
this in mind we reasoned that the concentration of drug should be high enough and the duration of 
exposure should be long enough to allow the formation of the expanded LVP.  We would then use a 
concentration of drug that exhibited no cytotoxic effects but maximized the expanded LVP.  Once these 
conditions were established we would then evaluate the drug’s potential to induce autophagy. 
Using lysotracker red (LTR), a fluorescent lysosomotropic molecule, we evaluated the dose dependency 
of 8 different lysosomotropic drugs’ abilities to cause an expanded LVP (Figure 2.2).  We found that the 
drugs exhibited varying degrees of cytotoxicity and potency in causing the expanded LVP.  This 
observation proved that a single uniform concentration of drug could not be used in future assessments.  
Instead, a unique concentration of drug was chosen for each of the 8 lysosomotropic drugs that 
exhibited no cytotoxicity but maximized the expanded LVP.  In general, the concentrations of drug that 
met this criteria ranged from high nanomolar to low micromolar levels (exact values are listed in Figure 
2.2). 
Following the optimization of drug concentrations, the autophagy induction potential was then 
evaluated for these lysosomotropic drugs.  One of the standard methods for evaluating autophagy 
induction involves the use of western blot analysis to monitor the processing of LC3 (microtubule-
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associated protein 1 (MAP1) light chain 3).  During normal autophagic processing, post-translational 
modification converts LC3 to the soluble cytosolic form LC3I.  LC3I is then lipidated with 
phosphatidylethanolamine to form LC3II which is bound to the autophagosome membrane.  LC3II levels 
can therefore be used as a protein marker for measuring the abundance of autophagosomes and by 
extension the levels of autophagy in cells (Tanida, Ueno et al. 2004, Kimura, Noda et al. 2007, 
Mizushima, Yoshimori et al. 2010).  Under conditions that lead to the induction of autophagy, the cell 
would theoretically initiate the creation of more autophagosomes which would thereby increase the 
abundance of LC3II relative to the corresponding control.  Autophagy induction can therefore be 
monitored by evaluating changes to the abundance of LC3II. 
Using the optimal concentrations of drug, determined from the dose response curves (Figure 2.2), each 
lysosomotropic drug was then evaluated for its ability to induce autophagy.  Interestingly, many of the 
lysosomotropic drugs caused an increase in the abundance of LC3II which likely indicates that these 
drugs were inducing autophagy (Figure 2.3).  Rapamycin was included in Figure 2.3 as a positive control 
as it is widely used as a known chemical inducer of autophagy (Sarkar, Floto et al. 2005, Rubinsztein, 
Gestwicki et al. 2007, Williams, Sarkar et al. 2008, Drake, Kang et al. 2010). 
Although this finding alone does not completely explain the entire expanded LVP, it does provide 
evidence supporting the possibility that autophagy might play a contributing role in the development of 
the expanded LVP seen in cells treated with these lysosomotropic perpetrator drugs. 
Chemical inducers of autophagy are capable of expanding lysosomal volume 
After establishing that the lysosomotropic drugs were capable of inducing autophagy we then needed to 
isolate autophagy and assess its capacity to modulate the steady state volume of lysosomes.  Although 
we would rationally consider autophagy induction to lead to an expansion in lysosomal volume, as it is a 
cellular process that delivers membrane and material to the lysosomes, we nonetheless found it 
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prudent to validate that autophagy induction is capable of expanding lysosomal volume.  We reasoned 
that if autophagy induction caused an increase in the steady state volume of lysosomes, then we should 
see a concomitant increase in the cellular accumulation of LTR within these cells. 
In this section we assessed the impact that autophagy induction had on the steady state volume of 
lysosomes.  Using three well characterized chemical inducers of autophagy (rapamycin, carbamazepine, 
or valproic acid) (Sarkar, Floto et al. 2005, Rubinsztein, Gestwicki et al. 2007, Williams, Sarkar et al. 2008, 
Drake, Kang et al. 2010), which are not considered to be lysosomotropic, we assessed the impact that 
elevated levels of autophagy had on the steady state volume of lysosomes.  By comparing the cellular 
uptake of the fluorescent lysosomotropic probe LTR, we were able to measure the relative changes in 
lysosomal volume caused by autophagy induction.  Interestingly, it was found that all three of the 
chemical inducers of autophagy were capable of expanding the steady state volume of lysosomes as 
indicated by the increase in the cellular accumulation of LTR compared to the vehicle treated control 
(Figure 2.4).   
Establishing that autophagy induction alone can expand the steady state volume of lysosomes was a key 
finding.  It provided evidence indicating that drug treatments leading to the induction of autophagy can 
ultimately result in an expansion of lysosomal volume.  Pairing this with the recent findings that the 
lysosomotropic perpetrator drugs were capable of inducing autophagy, we then had additional support 
for the hypothesis that autophagy induction might be contributing to the development of the expanded 
LVP. 
Chemical inducers of autophagy are capable of perpetrating a drug-drug interaction involving 
lysosomes 
Previous reports have indicated that autophagy can be induced in vitro and in vivo under various 
conditions that do not involve lysosomotropic drugs, including calorie restriction, genetic manipulations, 
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inhibition of insulin/insulin-like growth factor signaling, pharmaceutical interventions such as resveratrol 
(a polyphenol), and RNAi knockdown of genes required for optimal mitochondrial function (Madeo, 
Tavernarakis et al. 2010, Rubinsztein, Marino et al. 2011).  Considering the many routes by which 
autophagy can be induced, particularly calorie restriction, we envisaged the possibility that humans 
might be subjected to conditions leading to variable levels of autophagy in their tissues.  With this in 
mind, we found it prudent to evaluate the potential for elevated levels of autophagy to instigate a drug-
drug interaction involving lysosomes. 
In this section autophagy induction is evaluated for its capacity to perpetrate a drug-drug interaction 
involving lysosomes.  Using rapamycin, a non-lysosomotropic chemical inducer of autophagy (Sarkar, 
Floto et al. 2005, Rubinsztein, Gestwicki et al. 2007, Williams, Sarkar et al. 2008, Drake, Kang et al. 2010), 
WT human fibroblasts were subjected to a 2 day autophagy induction period prior to evaluating the 
cellular uptake of various clinically relevant drugs: propranolol, halofantrine, and naproxen.  Propranolol 
is a secondary amine-containing beta-blocker (structure illustrated in Figure 2.5), while halofantrine is a 
tertiary amine-containing antimalarial drug (structure illustrated in Figure 2.5).  Because of their weakly 
basic properties both of these drugs are considered to be lysosomotropic.  The cellular uptake of 
propranolol and halofantrine should therefore be sensitive to changes in the volume of the lysosomal 
system.  Included in these assessments is the non-steroidal anti-inflammatory drug naproxen which 
contains a carboxylic acid and is not considered to be lysosomotropic (structure illustrated in Figure 2.5).  
Naproxen therefore would not be expected to be sensitive to changes in the volume of the lysosomal 
system.   
Consistent with these expectations, elevated levels of autophagy induced by rapamycin caused a 
significant increase in the cellular accumulation of both propranolol and halofantrine but not naproxen 
(Figure 2.5).  These results indicate that chemical-inducers of autophagy can act as perpetrators of a 
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drug-drug interaction involving lysosomes.  We reasoned that under conditions that induce autophagy 
the steady state volume of lysosomes is increased which results in an increased capacity of these cells to 
accumulate lysosomotropic drugs.  Secondarily administered lysosomotropic drugs would therefore be 
subjected to cells with an enhanced lysosomal sequestration capacity.  Ultimately this condition would 
be expected to increase the cellular accumulation of the secondarily administered lysosomotropic drug 
(as seen in Figure 2.5). 
Lysosomotropic drugs are capable of impairing vesicle-mediated trafficking out of the lysosomes 
As discussed previously, the steady state volume of lysosomes is achieved when the rate of input of 
membrane and material into the lysosomes equals the rate of output of membrane and material from 
the lysosomes.  After implicating autophagy induction as a potential mechanism involved in the 
development of the expanded LVP seen in cells treated with the lysosomotropic perpetrator drugs, we 
then sought to explore how these drugs might influence the vesicle-mediated egress efficiency of 
membrane and material out of the lysosomes.  We reasoned that conditions leading to an impairment 
of lysosomal egress would ultimate result in an increase to the steady state volume of lysosomes. 
In this section the impact that 8 lysosomotropic perpetrator drugs had on the efficiency of vesicle-
mediated lysosomal egress was assessed using a dextran secretion assay.  Briefly, cells were exposed to 
a tritium labeled, membrane impermeable, dextran polymer that was allowed to accumulate in 
lysosomes using the pulse chase protocol previously established by Goldman et al. (Goldman, Funk et al. 
2009).  The release of dextran into the extracellular media was then monitored over a 24 hr time period.  
Conditions that impair or enhance vesicle-mediated lysosomal egress would be expected to result in a 
corresponding decrease or increase (respectively) in the extracellular release of the dextran polymer.   
Interestingly, we found that the lysosomotropic perpetrator drugs were capable of impairing the 
efficiency of vesicle-mediated lysosomal egress compared to the vehicle-treated control (Figure 2.6).  
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Knowing that these perpetrator drugs also induced autophagy, we evaluated the influence that 
autophagy alone has on vesicle-mediated trafficking out of the lysosomes (Figure 2.7).  All three of the 
chemical inducers of autophagy showed no impairment in lysosomal egress.  Instead they showed an 
enhancement in the lysosomal egress of the dextran polymer, indicating that they were increasing the 
efficiency of lysosomal egress.  Although this finding might seem to confound the results obtained with 
the lysosomotropic drugs, it is likely that despite the enhancement in lysosomal egress arising from the 
induction of autophagy, the perpetrator drugs are impairing lysosomal egress to such an extent that the 
overall egress efficiency is still lower than the vehicle treated control. 
Conclusion  
Recent work by Funk and Krise has identified a novel drug-drug interaction involving lysosomes whereby 
one lysosomotropic drug can cause an increase in the accumulation of a secondarily administered 
lysosomotropic drug (Funk and Krise 2012).  In this work they showed that the perpetrator drug caused 
a significant increase in the steady state volume of lysosomes, a condition referred to as the expanded 
lysosomal volume phenotype (expanded LVP).  This expanded LVP imparted an increase to the lysosomal 
sequestration capacity of the cells which ultimately resulted in an enhanced cellular accumulation of 
secondarily administered lysosomotropic drugs. 
Although Funk and Krise provided a well detailed description of the drug-drug interaction pathway, a 
mechanistic basis for the development of the expanded LVP was not provided.  The work presented in 
this chapter is a continuation of their work and reveals the importance that autophagy induction plays in 
the development of this phenomenon.   
The steady state volume of lysosomes results when the rate of input of membrane and material into the 
lysosomes equals the rate of membrane and material moving out of the lysosomes.  Logically, conditions 
that increase the rate of input or decrease the rate of output, or a combination of the two, could 
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conceivably result in an increase of lysosomal volume i.e., the formation of an expanded LVP.  We show 
that well known chemical inducers of autophagy are capable of expanding the steady state volume of 
lysosomes and that the induction of autophagy can lead to a drug-drug interaction similar to that seen 
with the lysosomotropic perpetrator drugs.  We then show that autophagy induction contributes to the 
development of the expanded LVP seen with the lysosomotropic perpetrator drugs.  We also show that 
these lysosomotropic drugs are capable of impairing the efficiency of vesicle-mediated lysosomal egress.   
Overall these results indicate that the expanded LVP perpetrated by lysosomotropic drugs is the result 
of an increased rate of input of membrane and material into the lysosomal system, via autophagy 
induction, and an impaired rate of the vesicle-mediated egress of membrane and material out of the 
lysosomes.  We propose that the combination of these two conditions ultimately results in an increase 
to the steady state volume of lysosomes and the development of the expanded LVP. 
We propose that these findings provide a greater understanding of the mechanisms underlying the 
variability seen in the pharmacokinetic properties of drugs administered to humans.  By virtue of their 
extensive accumulation in the lysosomes of peripheral tissues, lysosomotropic drugs tend to have a very 
large volume of distribution and half-life.  In addition these parameters often exhibit significantly large 
variability.  For example, the antiarrhythmic drug amiodarone has a reported steady state volume of 
distribution ranging from 40 to 84 L/kg and a terminal half-life ranging from 20 to 47 days (Chow 1996).  
Although the cause of this variability is likely multifaceted, we propose that changes in the levels of 
autophagy could account for a significant portion of this variability.  Our results indicate that patients 
experiencing conditions that induce autophagy would have peripheral tissues that possess a significantly 
greater capacity to accumulate lysosomotropic drugs.  Clinically, this would result in a larger volume of 
distribution and half-life for these drugs.  In light of recent reports that have identified many pathways 
leading to autophagy induction, particularly a calorie restricted diet (Madeo, Tavernarakis et al. 2010, 
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Rubinsztein, Marino et al. 2011), we feel that autophagy induction might become an increasingly 
important consideration in predicting the pharmacokinetic behavior of lysosomotropic drugs although 
future in vivo studies are required to fully characterize this drug-drug interaction mechanism.  
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Figure 2.1  Three well established biological process that can deliver membrane and material to the 
lysosomal system.  Each pathway (endocytic, biosynthetic, and autophagic pathway) is highlighted with 
a grey arrow. 
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Figure 2.2  Concentration-dependent cellular accumulation of LysoTracker Red (200 nM for 1 hour) in 
wild-type human fibroblasts with a 48 hour pretreatment of various lysosomotropic drugs measured by 
(inset) epifluorescence microscopy and whole cell lysates of approximately 500,000 cells.  For each inset 
the cell nuclei is designated with “N” and the scale bar represents 10 micrometers in length.  Cellular 
accumulation of LysoTracker Red was measured in fluorescence units and then normalized to protein.  
The normalized LTR uptake was then compared to the control condition (vehicle alone) and reported as 
a percentage of the control.  The drug concentrations used for the fluorescent micrographs was 
determined as the value that yielded the greatest expansion of lysosomal volume while showing no loss 
in viability or visible signs of toxicity: U18666A (2μM), quinacrine (2μM), propranolol (4μM), haloperidol 
(10μM), chloroquine (4μM), bupivacaine (100μM), lidocaine (100μM), imipramine (1μM).  
(Originally published in: J Pharm Sci. 2013 Aug 22. doi: 10.1002/jps.23706)  
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Figure 2.3  Western blot analysis of the protein markers of autophagy LC3BI/II (18kDa, 16kDa 
respectively) with a 48-hour treatment of various lysosomotropic drugs or vehicle alone.  The 
concentration of lysosomotropic drug used in these assessments (A) & (B) was as follows: U18666A 
(2μM), quinacrine (2μM), propranolol (4μM), haloperidol (10μM), chloroquine (4μM), bupivacaine 
(100μM), lidocaine (100μM), imipramine (1μM), amiodarone (5µM). 
(Originally published in: J Pharm Sci. 2013 Aug 22. doi: 10.1002/jps.23706) 
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Figure 2.4  Cellular accumulation of LysoTracker Red (200nM for 1 hour) in wild-type human fibroblasts 
with a 48-hour pretreatment of the autophagy inducers rapamycin (200nM), valproic acid (1.5mM), 
carbamazepine (50μM), or vehicle alone assessed by (A) epifluorescence microscopy and (B) whole cell 
lysates of approximately 500,000 cells (n=3).  In section (A) each cell nuclei is designated with “N” and 
scale bars represent 10 micrometers in length.  Cellular accumulation of LysoTracker Red in (B) was 
measured in fluorescence units and then normalized to protein.  The normalized LTR uptake was then 
compared to the control condition (vehicle alone) and reported as a percentage of the control.  The 
values represented in this plot are the mean +/- SD from three independent experimental evaluations 
(*, p <.02 by Student’s t-test). 
(Originally published in: J Pharm Sci. 2013 Aug 22. doi: 10.1002/jps.23706) 
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Figure 2.5  Cellular accumulation of the lysosomotropic drugs propranolol (200nM), halofantrine 
(200nM) or the non-lysosomotropic drug naproxen (5μM) with a 48-hour pretreatment of the 
autophagy inducer rapamycin (200nM) or vehicle alone.  Cellular accumulation of tritium-labeled 
propranolol and halofantrine was measured in radioactive units (DPM) and normalized to protein.  
Naproxen cellular accumulation was measured by LC-MS/MS and normalized to protein.  The normalized 
drug uptakes were then compared to the corresponding control sample devoid of rapamycin 
pretreatment, and the value is reported as a percentage of the control.  The values represented in this 
plot are the mean +/- SD from three independent experimental evaluations (*, p <.01 by Student’s t-
test). 
(Originally published in: J Pharm Sci. 2013 Aug 22. doi: 10.1002/jps.23706)  
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Figure 2.6  Vesicle-mediated lysosomal egress assessed by dextran secretion (24-hour release period) 
with a 48-hour pretreatment of various lysosomotropic drugs or vehicle alone.  Secretion of tritium- 
labeled dextran was measured in radioactive units (DPM) and normalized to protein.  The normalized 
dextran secretion was then compared to the control condition (vehicle alone) and reported as a 
percentage of the control.  The values represented in this plot are the mean +/- SD from three 
independent experimental evaluations (*, p <.05 by Student’s t-test).  The drug concentrations used 
were as follows: U18666A (2μM), quinacrine (2μM), propranolol (4μM), haloperidol (10μM), 
chloroquine (4μM), bupivacaine (100μM), lidocaine (100μM), imipramine (1μM). 
(Originally published in: J Pharm Sci. 2013 Aug 22. doi: 10.1002/jps.23706)  
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Figure 2.7  Vesicle-mediated lysosomal egress assessed by dextran secretion (24-hour release period) 
with a 48-hour pretreatment of the autophagy inducers rapamycin, carbamazepine, valproic acid, or 
vehicle alone.  Secretion of tritium-labeled dextran was measured in radioactive units (DPM) and 
normalized to protein.  The normalized dextran secretion was then compared to the control condition 
(vehicle alone) and reported as a percentage of the control.  The values represented in this plot are the 
mean +/- SD from three independent experimental evaluations (*, p < .05 by Student’s t-test). 
(Originally published in: J Pharm Sci. 2013 Aug 22. doi: 10.1002/jps.23706)  
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 Chapter 3. Time-dependent effects of lysosomotropic drugs on the biogenesis of lysosomes 
 
Introduction 
Understanding the sources of variability in the pharmacokinetic properties of administered drugs is 
vitally important in ensuring that the proper dosing regimen is prescribed to each patient.  Failure to 
adequately account for unexpected pharmacokinetic behavior can conceivably result in drug exposure 
levels that either fail to achieve the desired activity or rise to toxic levels.  With this in mind, 
lysosomotropic drugs should be rigorously evaluated as they represent a category of drugs that typically 
have unique pharmacokinetic properties including a large volume of distribution and half-life.  
Lysosomotropic drugs also exhibit a significant degree of inter- and intra-patient variability in these 
same pharmacokinetic parameters.  For example, the lysosomotropic drugs methadone, chloroquine, 
halofantrine, and amiodarone all exhibit a very wide range of reported values for their elimination half-
lives (Table 3.1) as stated by the manufacturers’ package insert and Ducharme et. al. (Ducharme and 
Farinotti 1996).   
In our evaluations of lysosomotropic drugs we have found that their total cellular accumulation is almost 
entirely accounted for by lysosomal sequestration (Figure 3.1), a finding that corroborates a similar 
report by Funk and Krise (Funk and Krise 2012).  With this in mind, we reasoned that the unique 
pharmacokinetic properties of these drugs, specifically their large volume of distribution, are primarily 
the result of lysosomal sequestration in the peripheral tissues.  Although the volume of distribution is a 
pharmacokinetic parameter that is often stated to be a constant (Shargel, Wu-Pong et al. 2005), we have 
begun to consider the possibility that it is a dynamic parameter that is subject to fluctuation.  Based on 
our knowledge that the cellular accumulation of lysosomotropic drugs is sensitive to changes in the 
lysosomal sequestration capacity of cells, we reasoned that conditions or cellular processes that lead to 
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increases or decreases in the lysosomal sequestration capacity of peripheral tissues could result in a 
significant change to the volume of distribution of lysosomotropic drugs.  Due to the proportional 
relationship between the volume of distribution and half-life, increases to a drug’s volume of 
distribution could foreseeably result in a longer half-life (Greenblatt 1985).  Based on this, it seems 
feasible that this mechanism could, at least in part, be contributing to the variability observed in the 
volume of distribution and half-life of lysosomotropic drugs. 
Inspired by the potential clinical ramifications of this hypothesis we have focused the efforts of the 
current chapter on evaluating the time- and concentration-dependent changes to lysosomes caused by 
exposing cells to one of three different lysosomotropic drugs that have a range of relative lipophilicities 
from low to high (Log P: methylamine  -0.63, propranolol 2.32, and halofantrine 7.93).  We have sought 
to characterize the changes occurring to the cellular accumulation of these drugs and provide a 
mechanistic basis for these observed changes.  Ultimately, this information could be used to explain, at 
least in part, some of the inter- and intra-patient variability seen in the pharmacokinetic parameters of 
lysosomotropic drugs. 
Materials and Methods 
Cell Lines and Reagents 
Wild-type (WT) human fibroblasts (catalogue # CRL-2076) were purchased from ATCC (Manassas, VA).  
All cells were cultured in glutamine-free DMEM supplemented with 10% FBS, 10mM HEPES, 1mM 
Sodium Pyruvate, and 2mM Glutamax and maintained at 37°C and 5% CO2.  Cells were routinely 
subcultured to maintain 50% to 90% confluency.  Experiments were carried out within 10 passages 
following removal from cryopreservation. 
Dulbecco’s phosphate buffered saline (D-PBS), Dulbecco’s modified Eagle’s medium (DMEM), HEPES, 
sodium pyruvate, glutamax, and Lysotracker Red DND-99 (LTR) were purchased from Invitrogen 
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(Carlsbad, CA).  Fetal bovine serum (FBS) was purchased from Atlanta Biologicals (Lawrenceville, GA).  
Halofantrine, propranolol, methylamine, laemmli buffer, Triton X-100 (TX-100), and sodium 
deoxycholate were purchased from Sigma-Aldrich (St. Louis, MO).  Pierce BCA protein assay kit was 
ordered from ThermoScientific (Rockford, IL).  Anti-beta actin antibody (catalogue #8H10D10) was 
purchased from Cell Signaling Technology (Danvers, MA).  Anti-TFEB antibody (catalogue #A303-673A) 
was purchased from Bethyl Laboratories Inc (Montgomery, TX).  The anti-LAMP1 monoclonal antibody 
(H4A3) developed by J. Thomas August and James E.K. Hildreth was obtained from the Developmental 
Studies Hybridoma Bank developed under the auspices of  the NICHD and maintained by the University 
of Iowa, Department of Biology (Iowa City, IA).  3[H]-halofantrine and 3[H]-propranolol were purchased 
from American Radiolabeled Chemicals, Inc. (St. Louis, MO).  14[C]-methylamine was purchased from 
Moravek Biochemicals (Brea, CA). 
 
Drug Accumulation Assays 
 
WT human fibroblasts were grown in plastic 12-well culture plates (Corning Life Sciences) at a seeding 
density of 10,000 cells per well.  All cell samples utilized to determine the time-dependent uptake of 
drug were grown for 8 days in a 12-well plate in order to control for variability in cellular confluency 
upon completion.  During the 8 day growth period the extracellular media was replaced with drug 
containing media (3[H]-propranolol at .06µCi/mL, 3[H]-halofantrine at .1µCi/mL or 14[C]-methylamine at 
.1µCi/mL) at the appropriate time in order to attain the indicated duration and concentration of drug 
exposure.  During this time period the media was refreshed every 48 hrs in order to maintain optimal 
nutrient conditions for cell growth.  To assess the total drug accumulation, the cells were immediately 
washed twice with 4°C D-PBS once the desired exposure time was achieved.  To assess the drug uptake 
by ion-trapping independent mechanisms, nigericin and monensin was spiked directly into the existing 
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cell culture media (final concentration of 10µM and 20µM, respectively) 2 hrs prior to reaching the 
desire drug exposure duration.  Once the desire drug exposure time was achieved, the cells were then 
washed twice with 4°C D-PBS.  The washed cells were then lysed using lysis buffer (50 mM tris base, 150 
mM NaCl, 1% NP40, pH titrated to 7.4 with HCl) for 30mins at 37°C.  The lysate was recovered from each 
well by aspiration using a standard pipette.  The quantity of radio-labeled drug was measured in DPMs 
using a Beckman LS 60001C liquid scintillation counter.  Background signal contributed from non-specific 
binding of drug to the plate surface was subtracted from each measurement.  Dilutions of each 
radiolabeled drug stock were performed to attain a standard curve relating DPMs to nanomoles of drug.  
Measured DPMs in the cell samples were then converted to nanomoles of drug.  Protein abundance was 
measured for each sample using the BCA method.  The calculated nanomoles of drug present in each 
sample was then normalized to mg protein.   
The ion-trapping dependent cellular accumulation of propranolol or halofantrine was determined 
mathematically by subtracting the ion-trapping independent cellular accumulation (nigericin/monensin 
treated samples) from the total cellular accumulation at each indicated time point.  In order to facilitate 
direct comparison of the cellular uptake of drug between the 5nM exposure and the 5µM exposure, the 
activity of the radiolabeled drug was held constant between the two conditions (.06µCi/mL 3H-
propranolol or .1µCi/mL 3H-halofantrine).  Unlabeled drug was then added to the radiolabeled-drug-
containing-media in order to achieve the total target concentration of drug.  A direct comparison of the 
drug accumulation for the 5nM and 5µM drug exposures could only be achieved with propranolol and 
halofantrine as the cellular accumulation of methylamine was below the limit of quantification at 
nanomolar concentrations. 
 
Drug Release Assay 
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WT human fibroblasts were grown in plastic 12-well culture plates at a seeding density of 20,000 cells 
per well.  The cells were exposed to 5µM propranolol (consisting of 4.995µM unlabeled propranolol and 
5nM of 3H-propranolol at a final activity of .06µCi/mL) or 5µM halofantrine (consisting of 4.995µM 
unlabeled halofantrine and 5nM 3H-halofantrine at a final activity of .1µCi/mL) for 6 days.  At the end of 
this 6 day exposure the extracellular media was replaced with drug-free media which marked time point 
zero of the drug washout period.  The drug-free extracellular media was replaced every 24hrs to 
maintain sink conditions.  At the indicated time points cells were then rapidly washed twice with 4°C D-
PBS.  The cells were then lysed for 30 min at 37°C using lysis buffer and the lysate was capture by 
aspiration using a standard pipette.  The quantity of tritium-labeled drug (propranolol or halofantrine) 
was measured in disintegrations per minute (DPM) using a Beckman LS 60001C liquid scintillation 
counter.  Background signal contributed from non-specific binding of drug to the plate surface was 
subtracted from each measurement.  Dilutions of each radiolabeled drug stock were performed to attain 
a standard curve relating DPMs to nanomoles of drug.  Measured DPMs in the cell samples were then 
converted to nanomoles of drug.  Protein abundance was measured for each sample using the BCA 
method.  Measured DPMs were then converted to nanomoles of drug and normalized to protein. 
 
Lysotracker Red Accumulation Assay 
 
WT human fibroblasts were grown in plastic 12-well culture plates at a seeding density of 20,000 cells 
per well.  The cells were exposed to vehicle or 5µM of propranolol or halofantrine for 6 days.  The 
extracellular media was refreshed after 2 days in order to maintain optimal nutrient conditions.  At the 
end of this 6 day exposure the extracellular media was replaced with drug-free media which marked 
time point zero of the drug washout period.  The drug-free extracellular media was replaced every 24hrs 
to maintain sink conditions.  At the indicated time points during the drug washout phase LTR cellular 
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accumulation was measured as previously described.(Funk and Krise 2012)  Briefly, LTR was spiked into 
the existing media to a concentration of 200nM and the cells were incubated at 37°C for 1 hour.  Cells 
were then rapidly washed twice with 4 °C D-PBS.  Cells were lysed with lysis buffer for 30mins at 37°C.  
The lysate was recovered from each well by aspiration using a standard pipette.  The quantity of LTR was 
determined by fluorescent signal in relative fluorescence units (RFU) using a Bio-Tek FL600 microplate 
fluorescence reader.  Background signal contributed from non-specific binding of LTR to the plate 
surface was subtracted from each measurement.  Protein abundance was measured for each sample 
using the BCA method.  Measured LTR signal (RFU) was then normalized to protein.  These normalized 
values were then compared to the control condition (vehicle treated) and depicted as a percentage of 
the control. 
 
Western Blot Analysis 
 
WT human fibroblasts were grown in 100mm plastic Petri dishes (Corning Life Sciences) at a seeding 
density of approximately 200,000 cells per dish.  The extracellular media was replaced with 5µM 
propranolol and the cells were exposed to the drug for the indicated duration (Figure 2.3).  The 
extracellular media was refreshed every 48 hrs in order to maintain optimal nutrient conditions for cell 
culture.  Upon reaching the desired duration of drug exposure, cells were quickly washed three times 
with 4°C D-PBS.  Whole cells were then lysed with RIPA buffer (150mM sodium chloride, 1% TX-100, 
0.5% sodium deoxycholate, 0.1% SDS, 50mM tris, pH 8.0, and the protease inhibitors APL & PMSF).  The 
protein abundance was then determined by the BCA method.  Protein samples were then mixed with 
Laemmli buffer (250mM Tris-HCl, 8% Sodium Dodecyl Sulfate (SDS), 40% Glycerol, 8% ß-
mercaptoethanol, .02% bromophenol).  Protein samples from whole cell lysates or isolated nuclear 
fractions (see method section Isolation of cell nuclei) were subjected to 12% sodium dodecyl sulfate-
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polyacrylamide gel electrophoresis (SDS-PAGE) for 120 mins.  The proteins were then transferred to a 
0.2 µm pore PVDF membrane (Millipore) using 300 V*hrs.  The PVDF membrane was then blocked using 
5% non-fat milk for 1hr at room temperature.  The PVDF membrane was then exposed to primary 
antibody (1:1000 anti-LAMP1, 1:30,000 anti-beta actin, or 1:3000 anti-TFEB) for two hrs, washed for 
5mins X3 in .2% TX-100/D-PBS to remove non-bound primary antibodies, and then exposed to 
secondary antibody (1:4000  goat anti-rabbit HRP or goat anti-mouse HRP) for two hrs and then washed 
for 5mins X3 in .2% TX-100/D-PBS.  Detection of HRP-conjugated antibody was achieved by 
chemiluminescence using Western Lightning-ECL (PerkinElmer) on autoradiograph film. 
 
Isolation of Cell Nuclei 
 
Isolation of the nuclear fraction of WT human fibroblasts was carried out as described.(Settembre, Di 
Malta et al. 2011)  Briefly, WT human fibroblasts were grown in 100mm plastic Petri dishes at a seeding 
density of approximately 200,000 cells per dish.  The extracellular media was replaced with 5µM 
propranolol and the cells were exposed to the drug for the indicated duration (Figure 2.3).  The 
extracellular media was refreshed every 48 hrs in order to maintain optimal nutrient conditions for cell 
culture.  Upon reaching the desired duration of drug exposure, cells were quickly washed three times 
with 4°C D-PBS.  Cells were then lysed using soft-lysis buffer (50mM Tris-HCl, 137.5mM NaCl, .5% TX, 
10% glycerol, 5mM EDTA, pH 8, and the protease inhibitors APL & PMSF) for 15mins at 4°C.  The petri 
dishes were then scraped using a cell scraper to liberate all cellular debris.  The soluble and insoluble 
portions of the cell lysate were then centrifuged for 3mins at 3,000g.  The supernatant was removed and 
the resulting nuclear pellet was washed twice with ice-cold D-PBS.  The remaining nuclear pellet was 
then solubilized in RIPA buffer. 
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Transmission Electron Microscopy 
 
WT human fibroblasts were grown in 175cm2 culture flasks for 6 days with vehicle alone or 5µM 
propranolol.  Media was refreshed every 48 hrs in order to maintain optimal nutrient conditions.  At the 
end of the 6 day time period the cells were removed and fixed using 0.25% glutaraldehyde for 2 hrs at 
room temperature.  Cells were then washed once and stained with osmium tetroxide 2% w/v in D-PBS 
for 1 hour at room temperature.  The cells were washed one time with D-PBS and stained with tannic 
acid 1% for one hour at room temperature.  The cells were then washed with water and stained with 
uranyl acetate 4% for 30mins at room temperature.  Following one wash step with water the cells were 
washed in progressively higher concentrations of ethanol until the wash reached 100% ethanol.  
Following the ethanol washes the cells were stained with propylene oxide.  Cells were then embedded 
in EPON resin.  All images were taken on an FEI Tecnai F20 XT Field Emission Transmission Electron 
Microscope. 
Sizing of the lysosomal structures was performed manually using the Image J software (freely available 
at http://rsbweb.nih.gov/ij/).   The data obtained from the manual sizing was then normalized to the 
surface area of cytosol present within the analyzed cell slice and then reported as counts per mm2.  
Lysosomes were divided into three distinct categories, primary, secondary, and lipid laden membrane 
whorls, using published descriptions of their structural features as a guide.(Fawcett 1981)  Briefly, small 
dense granules with homogenous contents were considered to be primary lysosomes.  Due to the 
excessive number of primary lysosomes present within each cell slice, the data present in Figure 3.5 B 
for primary lysosomes is representative of one cell slice (n=1) for each condition.  Larger bodies with 
heterogeneous content including undigested material were considered to be secondary lysosomes.  
Larger densely stained bodies with multiple concentric membrane-like whorls were considered to be 
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lipid-laden membrane whorls.  Data presented in Figure 3.5 B for secondary lysosomes and membrane 
whorls are representative of ten cell slices (n=10) for each condition. 
 
Results and Discussion 
Lysosomotropic drugs increase their own cellular accumulation and exhibit biphasic cellular 
accumulation.   
In vitro studies that evaluate the dynamics of drug uptake and release have proven to be a valuable tool 
in developing an understanding of the mechanisms underlying the variability observed in the activity 
and pharmacokinetic properties of drugs administered to humans (Sirotnak, Moccio et al. 1981, 
Leonessa, Jacobson et al. 1994, Demant and Friche 1998).  In chapters 1 and 2 we have detailed the 
phenomenon whereby lysosomotropic drugs caused an expansion in the lysosomal sequestration 
capacity of cells, a condition referred to as the expanded lysosomal volume phenotype (expanded LVP).  
Although we provided a mechanistic foundation for the development of the expanded LVP, we did not 
evaluate the time-dependent aspect of this phenomenon.  In the current section we have evaluated the 
dynamics of drug uptake of methylamine, propranolol, or halofantrine.  We have sought to answer the 
simple question, are these lysosomotropic drugs capable of increasing their own cellular accumulation 
as a result of the expanded LVP? 
To answer this first question, we initially investigated the cellular uptake of low nanomolar levels of a 
tritium-labeled drug (propranolol or halofantrine) following a 6 day exposure to the drug.  After 
establishing the cellular accumulation of the tritium-labeled drug we then repeated the experiment 
including a low micromolar concentration of native un-labeled drug.  We found that cells exposed to a 
low micromolar concentration of these drugs accumulated significantly more of the tritium-labeled 
probe versus the low nanomolar concentration (Figure 3.2 A).  Because the concentration of tritium-
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labeled probe was identical under these two conditions the radioactive abundance within the cells 
should be directly comparable.  The native unlabeled drug does not possess a radiolabeled element so it 
should therefore not contribute any additional signal in our assay regardless of its concentration.  These 
results support the notion that lysosomotropic drugs are capable of increasing their own cellular 
accumulation in a dose-dependent manner.  Due to the low abundance of methylamine cellular 
accumulation we were not able to determine if methylamine was capable of increasing its own cellular 
accumulation in a dose-dependent fashion as the low nanomolar concentration yielded a signal that was 
below our limit of quantification. 
After establishing this dose-dependent phenomenon we then sought to characterize the kinetic uptake 
profile for these two concentrations (i.e., the low nanomolar and low micromolar concentrations) over 
an 8 day period.  From these evaluations we hoped to glean information regarding when this dose-
dependent phenomenon was occurring.  Interestingly, we found that the kinetic uptake profile at the 
5µM concentration exhibited a bi-phasic characteristic for both propranolol and halofantrine (Figure 3.2 
B).  Similar to other published work, an initial steady state was reached after a short period of time with 
propranolol achieving the initial steady state after a few hours and halofantrine after one day (Figure 3.2 
B).  Importantly, the kinetic uptake profile at the 5nM concentration failed to exhibit a biphasic 
characteristic for both propranolol and halofantrine (Figure 3.2 C).  The difference in the kinetic uptake 
profiles between the low micromolar versus the low nanomolar concentrations was consistent with the 
dose-dependent phenomenon that we observed in Figure 3.2 A.  Another interesting observation was 
that the much more hydrophilic molecule, methylamine, did not exhibit a biphasic kinetic uptake profile 
at the 5µM concentration (Figure 3.2 C).  As mentioned previously, the 5nM kinetic uptake profile for 
methylamine could not be assessed due to analytical limitations.   
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Propranolol and halofantrine increase the lysosomal ion-trapping capacity of cells in a time-
dependent fashion.   
The total cellular accumulation of lysosomotropic drugs is achieved from the additive effects of two 
separate mechanisms, ion trapping-dependent and ion trapping-independent mechanisms.  The ion 
trapping-independent mechanisms includes drug-binding to components such as intracellular proteins, 
lipid membranes, and DNA.  Changes in the cellular uptake of lysosomotropic drugs could conceivably 
occur due to changes in one or both of these mechanisms.  In this section we have sought to 
characterize the contribution that ion trapping-dependent and ion trapping-independent mechanisms 
play in the cellular uptake of propranolol and halofantrine.   
To delineate the contribution that each of these cellular uptake mechanisms were exhibiting we 
employed the use of nigericin and monensin.  These small molecule drugs are capable of carrying 
hydrogen ions across lipid bilayers thereby dissipating the pH gradients existing within the cell, i.e., 
alkalinizing the lysosomal pH.  To determine the contribution of each cellular uptake mechanism we first 
measured the total cellular uptake of propranolol or halofantrine under normal conditions.  This value 
represented the drug uptake due to both ion trapping-dependent and ion trapping-independent 
mechanisms.  In parallel to this assessment we also measured the cellular accumulation of propranolol 
or halofantrine in the presence of nigericin and monensin.  Disrupting the pH gradients within the cells 
would result in the release of any drug that was accumulating due to ion trapping.  The cellular uptake in 
nigericin/monensin treated cells would therefore represent only the ion trapping-independent 
mechanisms.  By subtracting the ion trapping-independent value from the total uptake value we could 
arrive at the cellular uptake due to ion trapping-dependent mechanisms.  Using this approach we were 
able to characterize how the ion trapping-dependent mechanisms changed over the course of an 8 day 
drug treatment (Figure 3.3).  Figure 3.3 illustrates that the ion trapping based accumulation of these 
drugs increases significantly for both 5µM propranolol and 5µM halofantrine. 
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Hydrophobic amines increase nuclear localization of TFEB, increase the expression of LAMP1, and 
increase the abundance of smaller secondary lysosomes and lipid-laden lysosomes.   
Following the observation that both propranolol and halofantrine caused a significant and progressive 
increase in the ion trapping-dependent component of their total cellular uptake (Figure 3.3), we next 
sought to explore the cellular mechanisms that might be involved in this phenomenon.  Based on the 
theory of ion trapping, we reasoned that there were two conceivable changes that can occur within the 
cells to explain our observations.  The pH gradients that exist between the lysosomal lumen and the cell 
cytosol and extracellular space are vital for the ion trapping mechanism.  Increases to this pH gradient, 
i.e., hyper-acidification of the lysosomal lumen, could result in an enhanced ion trapping-dependent 
accumulation of lysosomotropic drugs (de Duve, de Barsy et al. 1974).  To explore this possibility we 
employed the use of a pH sensitive fluorophore (oregon-green) conjugated to a membrane 
impermeable dextran polymer.  After localizing this polymer to the lysosomes we then assessed the pH 
within the lysosomal lumen.  We found that cells exposed to 5µM propranolol for 4 days failed to cause 
a significant decrease in the pH of the lysosomes (Figure 3.4). 
After ruling out the possibility of lysosome hyper-acidification we then explored alternative mechanisms 
to explain our observations.  In the theory of ion trapping the volume of lysosomes can also influence 
the total cellular accumulation of lysosomotropic drugs (de Duve, de Barsy et al. 1974).  We envisaged 
several possible ways in which the volume of the lysosomes could be increasing.  First, the total number 
of lysosomes could increase inside the cell thereby resulting in an overall increase in the lysosomal 
volume.  Second, the diameter of the lysosomes could also increase which would result in a 
corresponding increase in the lysosomal volume.  Last, there could conceivably be a combination of 
these two possibilities.  To determine which of these possibilities were at play we performed a 
quantitative analysis of the diameter and overall abundance of lysosomes in cells treated for 6 days with 
or without exposure to 5µM propranolol using electron microscopy (Figure 3.5 A, B).  In this analysis, we 
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categorized lysosomes as either primary, secondary, or those containing multiple concentric membrane 
whorls (lipid-laden) according to previously published work (Fawcett 1981).  We then manually sized 
these lysosomes and reported the abundance and size distribution per surface area of cell cytosol.  
Interestingly, we found that propranolol caused a significant increase in the number of primary 
lysosomes seemingly without affecting the size distribution (Figure 3.5 B).  Propranolol also caused an 
increase in the abundance of 500nm to 1500nm sized secondary lysosomes (Figure 3.5 B).  Finally, the 
frequency of lysosomes containing multiple concentric membrane whorls also significantly increased 
(Figure 3.5 B).  Overall, propranolol caused a significant increase in the abundance of all three categories 
of lysosomes.  These results are consistent with the observed increase in both the total cellular 
accumulation of propranolol (Figure 3.2), and ion trapping-dependent accumulation of propranolol 
(Figure 3.3).   
To corroborate the results obtained from the ultrastructure analysis of lysosomes we also measured the 
total cellular abundance of LAMP-1 (lysosome-associated membrane protein 1) with the rationale that if 
increases to the abundance of lysosomes were indeed taking place then a corresponding increase in 
LAMP-1 should also become evident.  We found that 5µM propranolol caused a progressive time-
dependent increase in LAMP-1 starting after 1 day of propranolol exposure (Figure 3.5 C).  We also 
found a similar result in cells treated with 5µM halofantrine (Figure 3.6).  These results are consistent 
with the observations made in Figure 3.5 B. 
Having established that lysosomotropic drugs are capable of causing an increase in the number of 
lysosomes we next sought to determine the cellular mechanisms that might be underlying these 
observed effects.  Sardiello and coworkers have recently identified transcription factor EB (TFEB) as a 
master regulator of lysosome biogenesis which positively regulates genes included in the Coordinated 
Lysosomal Expression and Regulation (CLEAR) network (Sardiello, Palmieri et al. 2009).  With this in 
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mind, we tested the potential involvement of TFEB in the development of the drug-induced lysosome 
proliferation observed in Figures 3.5 B, 3.5 C, 3.6.  Under normal cellular conditions TFEB is primarily 
localized to the cell cytosol.  Under conditions leading to the activation of TFEB, i.e., conditions that 
enhance lysosomes biogenesis, TFEB translocates from the cell cytosol to the nucleus where it initiates 
to expression of lysosomes-associated genes (Sardiello, Palmieri et al. 2009, Settembre, Di Malta et al. 
2011).  In our analysis of propranolol treated cells, we found that the nuclear abundance of TFEB 
increased progressively in a time-dependent fashion starting after one day of exposure (Figure 3.5 C).  
This TFEB activation roughly coincided with the increase in LAMP-1 expression and enhanced cellular 
uptake of propranolol and halofantrine. 
The release of drugs from cells occurs faster than the reversal of the expanded lysosomal volume 
phenotype.   
After establishing the dynamic cellular uptake of propranolol and halofantrine, TFEB activation, and the 
ensuing expanded LVP, we next sought to determine the reversibility of this phenotype.  In this section 
we measured the kinetic release of propranolol or halofantrine from cells under sink conditions (drug-
washout) and compared that with the recovery rate to a normal lysosomal volume phenotype (recovery 
rate).  In order to evaluate the persistence of the expanded LVP, we measured the cellular uptake of the 
fluorescent lysosomotropic probe lysotracker red (LTR) as a surrogate marker for lysosomal volume.  The 
rate at which the LTR uptake values decline to 100% of control represents the “recovery rate”. 
Interestingly, we found that the drug-washout rate for propranolol could exceed the recovery rate 
(Figure 3.7 A).  This suggests that the expanded LVP is likely secondary to the accumulation of drug, i.e., 
propranolol is initiating some downstream event that ultimately results in the expanded LVP.  In 
contrast to propranolol, halofantrine exhibited a close parallel between the rate of drug-washout and 
the recovery rate (Figure 3.7 B).  The difference between propranolol and halofantrine could likely be 
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the result of widely different lipophilicities between the two drugs.  Halofantrine is significantly more 
lipophilic which could foreseeably result in reduced rates of drug-washout.    
Conclusion 
Lysosomtropic drugs tend to have unique pharmacokinetic properties including a very large volume of 
distribution and a long half-life (Shepard and Falkner 1990, Gong, Zhao et al. 2007, Zheng, Zhang et al. 
2011).  These drugs also tend to exhibit a significant degree of intra- and inter-patient variability in these 
same pharmacokinetic parameters.  Understanding the sources of variability in the pharmacokinetic 
properties of administer drugs is immensely important in ensuring that the proper dosing regimen is 
prescribed to each patient.  Failure to adequately account for conditions or diseases that cause 
unintended changes to the pharmacokinetic behavior of drugs can potentially lead to lack of efficacy 
(inadequate drug exposure) or even toxicity (drug exposures that are too high), particularly for drugs 
with narrow therapeutic windows. 
With this in mind, we have investigated possible mechanisms that can contribute to the large degree of 
variability seen in the pharmacokinetic properties of lysosomotropic drugs.  For example, methadone, 
chloroquine, halofantrine, and amiodarone all exhibit a very wide range of reported values for their 
elimination half-lives (Table 3.1) as stated by the manufacturers’ package insert and Ducharme et. al. 
(Ducharme and Farinotti 1996).  The elimination half-life is a dependent variable that is inversely 
proportional to clearance and proportional related to the volume of distribution (Greenblatt 1985).  
Traditionally, changes in the elimination half-life of drugs have been attributed to alterations in drug 
clearance while the volume of distribution was considered to be a constant parameter (Shargel, Wu-
Pong et al. 2005).  In the current chapter we have explored the possibility that the volume of 
distribution of lysosomotropic drugs is a dynamic pharmacokinetic parameter that can exhibit significant 
fluctuations. 
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We and others have shown that the extensive entrapment of lysosomotropic drugs in the lysosomes 
accounts for almost all of the cellular accumulation of these drugs (Figure 3.1) (Funk and Krise 2012, 
Logan, Kong et al. 2013).  This is a fascinating observation as the lysosomes only account for 
approximately 1% of the total cellular volume.  With this in mind, relatively minor changes to the 
lysosomal sequestration capacity of cells could potentially result in large changes in the degree of 
peripheral tissue accumulation ultimately influencing the volume of distribution for these drugs.  
Conditions or diseases that result in changes to the lysosomal sequestration capacity of cells could 
therefore provide the basis for the variability in the elimination half-life of these drugs.   
We and others have reported a drug-drug interaction involving lysosomes whereby the cellular 
accumulation of one drug could influence the cellular accumulation of a secondarily administered drug 
(Daniel and Wojcikowski 1997, Daniel and Wojcikowski 1999, Funk and Krise 2012).  In light of this work, 
we have focused the effort of the current chapter on characterizing the time-dependent effects that the 
perpetrator drug exhibits on the lysosomes.  We also sought to define the cellular processes that 
contribute to these observed changes.  In addition, we sought to determine if these lysosomotropic 
drugs were capable of increasing their own cellular accumulation. 
We have examined the time-dependent cellular accumulation of 3 lysosomotropic molecules that 
possess a large range of lipophilic character from a low Log P to a high Log P (methylamine  -0.63, 
propranolol 2.32, and halofantrine 7.93) (Figure 3.2).  In this assessment we observed that propranolol 
and halofantrine exhibited a biphasic cellular accumulation in that they both reached an initial steady 
state after a relatively short period of time, a finding that is similar to other reports detailing the drug 
uptake of methotrexate and the weakly basic anticancer drugs vinblastine and daunorubicin (Sirotnak, 
Moccio et al. 1981, Leonessa, Jacobson et al. 1994, Demant and Friche 1998).   
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After approximately two days of drug exposure the cells then exhibited a secondary accumulation phase 
which ultimately resulted in a 3-fold increase in drug levels compared to the initial 1 day steady-state 
(Figure 3.2 B).  Interestingly, this biphasic cellular accumulation was not observed with methylamine.  
Although methylamine is considered to be lysosomotropic, it has a significantly lower lipophilicity 
relative to the other two drugs.  We reasoned that methylamine’s failure to exhibit this same biphasic 
cellular accumulation was due to its relatively low lipophilicity and the ensuing total cellular uptake that 
was significantly lower than propranolol and halofantrine (.15nmol/mg protein, 2.5nmol/mg protein, 
26nmol/mg protein, respectively) (Figure 3.2 B).  Consistent with this reasoning, we showed that cells 
incubated with low nanomolar concentrations of propranolol or halofantrine failed to exhibit the 
biphasic cellular accumulation (Figure 3.2 C).   
To our knowledge this is the first study reporting a biphasic cellular accumulation phenomenon in 
cultured cells treated with lysosomotropic drugs.  However, other groups have also observed that the 
cellular accumulation of lysosomotropic drugs (e.g., amiodarone, chloroquine, propranolol, and 
chlorpromazine) can steadily increase over an 8 day time period (Honegger, Scuntaro et al. 1995, 
Scuntaro, Kientsch et al. 1996).  Honegger and coworkers found that the steadily increasing 
accumulation of these lysosomotropic drugs was accompanied by an increase in the intracellular 
accumulation of phospholipids (i.e., phosopholipidosis).  They reasoned that the increase in intracellular 
phospholipids (phospholipidosis) provided additional lipid-binding sites for these cationic drugs and it 
was by virtue of these additional binding sites that the lysosomotropic drugs exhibited a time-
dependent increase in their cellular accumulation (Honegger, Scuntaro et al. 1995, Scuntaro, Kientsch et 
al. 1996).     
Although we found this to be an intriguing and well-reasoned hypothesis, we sought to more fully 
evaluate the mechanisms associated with the observed increases in the cellular accumulation of 
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propranolol and halofantrine.  By employing the use of 2 ionophores, nigericin and monensin, we 
separately measured the contribution that ion trapping-dependent and ion trapping-independent 
mechanisms played in the total cellular accumulation of these drugs.   
Our results indicated that the ion trapping-independent mechanisms (i.e., binding to intracellular 
proteins, lipid membranes, and DNA) exhibited a steadily increasing contribution to the total cellular 
accumulation of propranolol and halofantrine over the 8 day time period (Figure 3.8), a finding that 
corroborates the work by Honegger and colleagues.  However, we also found that the ion trapping-
dependent mechanisms also increased over this 8 day time period (Figure 3.3).  This is a significant 
finding because it implies that phospholipidosis alone cannot account for all of the time-dependent 
increases seen in the cellular accumulation of these drugs.  We reasoned that the volume of the 
lysosomes must also be increasing in a time-dependent manner and that this mechanism is also 
contributing to time-dependent increase in drug uptake. 
After establishing that an expansion in lysosomal volume was contributing to the time-dependent 
increases in the cellular accumulation of propranolol and halofantrine, we next sought to determine the 
basis for this phenomenon.  Others have reported observations where lysosomotropic drugs were 
capable of increasing lysosomal volume by causing massive osmotic swelling to the lysosomes, a process 
called vacuolization (Yang, Strasser et al. 1965, Finnin, Reed et al. 1969, Ohkuma and Poole 1981, 
Morissette, Lodge et al. 2008).  In these evaluations the expansion in lysosomal volume was so massive 
that the lysosomes became visible by light microscopy.  Although this finding is interesting, it is likely a 
phenomenon that is only achievable in an in vitro scenario as the drug concentrations required to 
achieve these results are in the millimolar range.  We found it unlikely that lysosome vacuolization was 
contributing to the observed increase in lysosome volume seen in Figure 3.3 because we failed to see 
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any visible lysosome vacuolization by light microscopy, and we evaluated drug concentrations that were 
approximately 3 orders of magnitude lower than the aforementioned vacuolization experiments. 
After ruling out lysosomal vacuolization, we then attempted to uncover the basis for this lysosomal 
volume expansion by examining the ultrastructure of lysosomes in cells treated for 6 days with or 
without 5µM propranolol.  We had envisaged two distinct mechanisms that could lead to an increased 
lysosomal volume.  First, the lysosomes could be coalescing (homotypic fusion) or fusing with other 
vesicles (heterotypic fusion) which could ultimately result in an increase in lysosomal volume.  Secondly, 
the cell could be generating more lysosomes via the biosynthetic route.  Finally, there could be a 
combination of these two mechanisms.  Our results indicated that propranolol treatment caused an 
increase in the number of primary lysosomes and an increase in the number of smaller diameter 
secondary lysosomes.  There was also an observed increase in the number of lysosomes containing 
concentric membrane whorls (lipid-laden) lysosomes, which is consistent with previous reports detailing 
drug-induced phospholipidosis (Xia, Ying et al. 2000, Anderson and Borlak 2006) 
These results provide an interesting window into the mechanisms underlying the development of the 
expanded lysosomal volume seen with propranolol treatment.  The lysosome is a dynamic organelle that 
receives membrane and material from many cellular pathways such as phagocytosis, endocytosis, 
autophagy, and the biosynthetic pathway (Kornfeld and Mellman 1989, Luzio, Poupon et al. 2003, Saftig 
and Klumperman 2009).  An increase in the normal homeostatic levels of any of these pathways could 
conceivably result in an increase to the steady state volume of lysosomes.  On the other side of the 
mass-balance equation are pathways that can carry membrane and material away from the lysosomes.  
Although significantly less is known about these mechanisms, they too must represent an important 
pathway that can be controlled by the cell.  Interestingly, Luzio and coworkers have identified a 
lysosomal egress pathway that involves a heterotypic fusion event between lysosomes and late 
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endosomes resulting in the formation of a “hybrid organelle” (Luzio, Poupon et al. 2003, Luzio, Pryor et 
al. 2005).  They hypothesized that this hybrid organelle then stimulates the formation of small transport 
carrier vesicles that help extract membrane and material from the hybrid organelle, ultimately resulting 
in the reformation of the primary lysosome (Bright, Reaves et al. 1997).  With this in mind, we reasoned 
that conditions interfering with late endosome-lysosome fusion would result in a greater number of 
primary lysosomes.  Consistent with this hypothesis, we found that the number of primary lysosomes 
increased dramatically with a prolonged treatment of propranolol (Figure 3.5 B).  Previous reports have 
also observed impaired late endosome-lysosome fusion with the treatment of lysosomotropic drugs 
using different analytical techniques (Kaufmann and Krise 2008).   
In addition to impaired fusion competency between the late endosomes and lysosomes, we also 
conceived the possibility that these lysosomotropic drugs might be capable of impairing membrane 
fission events, i.e., vesicle-mediated trafficking away from lysosomes.  We reasoned that impaired 
vesicle-mediated trafficking away from lysosomes would manifest as perturbation in the normal size 
distribution of secondary lysosomes (hybrid lysosomes) as these bodies would be unable to revert back 
to primary lysosomes.  The histogram presented in Figure 3.5 B shows that the size distribution of 
secondary lysosomes has dramatically shifted, resulting in an increased abundance of 500nm to 1500nm 
diameter secondary lysosomes.  In corroboration of this idea, the results of the dextran secretion assay 
also supported the notion that lysosomotropic drugs can impair the vesicle-mediated egress efficiency 
out of the lysosomal system (Figure 2.6). 
The steady state lysosomal volume can also be influenced by pathways that bring membrane and 
material into the lysosomal system (i.e., endocytosis, autophagy, phagocytosis, and the biosynthetic 
pathway).  As we showed in Chapter 2, induction of autophagy can result in an increased steady state 
volume of lysosomes (Figure 2.4).  In this section we have sought to explore another input pathway, the 
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biosynthetic route (Figure 2.1).  An increase in the normal homeostatic level of this pathway could 
conceivably result in a greater number of lysosomes and by extension a greater steady state volume of 
lysosomes.  After observing that propranolol and halofantrine both exhibited a biphasic cellular 
accumulation we hypothesized that at some point prior to the secondary accumulation phase cells are 
up-regulating lysosome biogenesis.  Fortunately, Sardiello and coworkers have recently identified 
transcription factor EB (TFEB) as a master regulator of lysosome biogenesis and as a driver of autophagy 
(Sardiello, Palmieri et al. 2009, Settembre, Di Malta et al. 2011).   
With this recent discovery in mind, we evaluated the potential involvement of TFEB in the development 
of the expanded lysosomal volume phenotype.  In its inactive form TFEB is normally localized within the 
cell cytosol, but during activation TFEB translocates to the cell nucleus.  We found that cells treated with 
a low micromolar concentration of propranolol exhibited a time-dependent activation of TFEB (Figure 
3.5 C).  As expected, TFEB activation occurred after 1 day, just prior to the secondary accumulation 
phase beginning at approximately 2 days of propranolol exposure (Figure 3.2 B). 
To corroborate these findings implicating TFEB activation we also evaluated the time-dependent 
changes to the cellular abundance of LAMP-1 (lysosome associated membrane protein-1) which can be 
used as a surrogate marker for lysosome abundance (Fukuda 1991, Furuta, Yang et al. 1999).  If 
lysosome biogenesis was indeed being unregulated, we would expect to see a concomitant increase in 
the abundance of LAMP-1.  As Figures 3.5 C and 3.6 illustrates, the abundance of LAMP-1 increases in a 
time-dependent manner.  Importantly, the increase in LAMP-1 abundance occurs at relatively the same 
time as TFEB activation (1 day of exposure).  Collectively, these results support the hypothesis that TFEB 
activation is contributing to the drug-induced expansion in lysosomal volume seen in cells treated with 
lysosomotropic drugs. 
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The information presented thus far has detailed the dynamic cellular uptake of both halofantrine and 
propranolol and the ensuing changes that occurred to the lysosomes as a result of these exposures.  In 
addition to these characterizations we have also measured the rate at which these lysosomal changes 
revert back to normal, i.e., the rate at which the lysosomal volume returns back to 100% of control.  In 
order to test this we incubated cells with a low micromolar concentration of propranolol or halofantrine 
for 4 days which was enough time to allow the formation of the expanded LVP.  The extracellular media 
was then replaced with drug-free media, a time point which marked the beginning of the drug-washout 
period.  During this drug-washout period both the lysosomal volume and intracellular drug 
concentrations were measured over time (Figure 3.7).   
The results of these experiments allowed two important conclusions to be made.  First, the drug-
induced expansion in lysosomal volume appears to be fully reversible.  But, depending on the 
lysosomotropic drug, the recovery-rate can be dramatically different.  For example, the lysosomal 
volume in the propranolol treated condition is fully recovered after only a few hours of drug-washout 
(Figure 3.7 A), while the halofantrine treated cells required several days to recover back to control levels 
(Figure 3.7 B).  It is important to note that this difference in recovery-rate correlates with the rate of 
drug-release from the cells.  This finding is to be expected as we have previously determined that the 
expanded LVP is dose-dependent (Figure 3.2 B compared to 3.2 C).  Secondly, the data presented in 
Figure 3.7 A illustrates that the release of drug can occur faster than the recover-rate.  This is an 
interesting finding that suggests that the expanded LVP is not the direct result of drug accumulation, as 
seen with the osmotic swelling of lysosomes in the vacuolization process.  Instead, this implies that 
propranolol is influencing some downstream process, such as membrane fusion or membrane fission 
that is required for vesicle-mediated transport.  Unlike propranolol, the cellular release of halofantrine 
did not precede the recovery of lysosomal volume likely because the kinetics of drug-release was the 
rate-limiting process (Figure 3.7 B). 
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The data presented in this chapter provides valuable insight into the underlying mechanisms involved in 
how lysosomotropic drugs can alter lysosomes and increase their own cellular accumulation.  Although 
these findings are compelling and interesting, they must be followed with comprehensive in vivo studies 
to determine the full impact of this phenomenon in a clinical setting. 
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Drug name Elimination half life  
methadone 8-59 hours 
chloroquine 20-60 day 
halofantrine 6-10 days 
amiodarone 15-100 days 
 
 
 
 
Table 3.1  A table depicting the reported values for the elimination half-lives of four different 
lysosomotropic drugs.  Values are obtained from the package inserts provided by the drug 
manufacturers. 
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Figure 3.1  Lysosomal sequestration of propranolol accounts for a vast majority of propranolol cellular 
accumulation.  WT human fibroblasts were treated with 5µM tritium labeled propranolol (.06µCi/mL) 
for 2 days.  Following the end of the 2 day treatment the lysosomal pH gradient was either dissipated 
with 10µM nigericin and 20µM monensin (Uptake without lysosomal sequestration) or left intact 
(Uptake with lysosomal sequestration).  The total cellular accumulation of the tritium labeled probe was 
then depicted as counts per minute (cpm) normalized to the cellular protein (µg protein).     
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 Figure 3.2  Concentration and time dependent cellular accumulation of weakly basic compounds in WT 
human fibroblasts.  (A) Relative cellular accumulation of propranolol or halofantrine after an 8 day 
exposure to the presence of 5nM tritium labeled drug (final activity of .06µCi/mL or .1µCi/mL, 
respectively) or 5nM tritium labeled drug plus 5µM unlabeled drug (final activity of .06µCi/mL or 
.1µCi/mL, respectively) in the cell culture media showing that these drugs are capable of increasing their 
own cellular accumulation in a dose dependent manner.  (B) Time dependent cellular accumulation of 
5µM propranolol, 5µM halofantrine, or 5µM methylamine measured using radio-labeled compounds 
(final activity of .06µCi/mL, .1µCi/mL or .1µCi/mL, respectively).  (C) Time dependent cellular 
accumulation of 5nM propranolol or halofantrine measured using radio-labeled drugs (final activity of 
.06µCi/mL or .1µCi/mL, respectively). 
MethylamineHalofantrinePropranolol
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Figure 3.3  Time dependent changes in the ion trapping-based cellular accumulation of (A) propranolol 
or (B) halofantrine in WT human fibroblasts during an 8 day time period with the extracellular drug 
concentration held constant at 5µM. 
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Figure 3.4  Lysosomal pH measurements of WT human fibroblasts exposed to 4 days of vehicle (control), 
5µM propranolol, or lysosomal pH disruption (nigericin/monensin).  Lysosomal pH was determined 
through the use of oregon-green dextran as described in the materials and methods section. 
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Figure 3.5  Prolonged propranolol treatment (5µM) induces changes to the ultrastructure of WT human 
fibroblast and the expression and localization of cellular proteins.  (A) Transmission electron 
micrographs of cells treated for 6 days with vehicle (control) or 5µM propranolol showing that 
propranolol treatment increases the number of visible lipid-laden membrane whorls (intracellular dark 
circular bodies).  (B) Quantitative analysis of the size distribution of primary lysosomes, secondary 
lysosomes, and membrane whorls in cells treated for 6 days with vehicle (control) or 5µM propranolol.  
Insets depict a representative example of the associated structure.  Total counts are normalized to the 
surface area of cell cytosol analyzed within the cell slice.  (C) Westernblot analysis depicting the time 
dependent increase in LAMP1 expression and the time dependent activation (cytosol-to-nuclear 
translocation) of transcription factor EB (TFEB) following exposure to 5µM propranolol. 
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Figure 3.6  Western blot analysis depicting the time-dependent increase of LAMP1 abundance in WT 
human fibroblasts.  Each lane contains approximately 25µg of whole-cell protein from cells exposed to 
5µM halofantrine for the indicated exposure time. 
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Figure 3.7  
Comparative analysis of the time dependent cellular release of drug from WT human fibroblasts to the 
rate of reversal of the expanded lysosomal volume phenotype.  Cells were pretreated with (A) 5µM 
propranolol or (B) 5µM halofantrine for 6 days.  Following the pretreatment the extracellular media was 
replaced with drug free media and the rate of drug release and the cellular uptake of lysotracker red 
was analyzed at specified time points. 
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Figure 3.8  Time dependent changes in the ion trapping-independent cellular accumulation mechanisms 
of (A) propranolol or (B) halofantrine in WT human fibroblasts during an 8 day time period with the 
extracellular drug concentration held constant at 5µM. 
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Chapter 4. Structure activity relationship of lysosomotropic molecules their ability to induce an 
expanded lysosomal volume phenotype 
 
Introduction 
In the previous chapters we have detailed the ways in which lysosomotropic drugs can cause an 
expanded lysosomal volume phenotype (expanded LVP) and discussed the potential clinical 
ramifications of this phenomenon.  In this chapter we have sought to explore how specific 
physicochemical properties of lysosomotropic molecules relate to their potency in eliciting this 
expanded LVP.   
In the drug discovery process pharmaceutical scientists frequently assess a drug candidate’s potential to 
cause toxicity or perpetrate a drug-drug interaction.  From a health and safety stand-point this can 
reduce the chance that unsafe drugs are brought to market.  From an economic standpoint these 
assessments can ultimately save companies vast amounts of research and development resources by 
either redirecting efforts to a more viable drug candidate or by developing countermeasures to 
overcome the identified safety issues.   
The initial evaluations of a drug candidate’s potential to cause toxicity can be performed in silico using 
structure activity relationships that have been established for unsafe drug-drug target interactions.  For 
example, drug candidates are routinely screened for their potential to interact with the human ether-a-
go-go channel (hERG-channel), a potassium ion channel that is critical for proper cardiac function 
(Vandenberg, Perry et al. 2012, Rayan, Falah et al. 2013).  Through the use of in vitro screening 
techniques and protein crystal structure analysis a structure activity relationship has been developed 
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that can help predict possible drug-hERG-channel interactions (Tang, Kang et al. 2001, Vandenberg, 
Perry et al. 2012).  Critical to the development of this structure activity relationship was a well-defined 
biological response, in this case the inhibition of hERG-channel activity, and a clinical imperative that 
necessitated the elucidation of the structure activity relationship, e.g., hERG-channel interactions can 
lead to cardiac arrhythmias and sudden cardiac arrest (Rampe and Brown 2013).  Although the clinical 
ramifications of the expanded LVP are likely not as catastrophic as those seen with hERG-channel 
interactions, we nonetheless feel that the expanded LVP (and the ensuing drug-drug interaction 
involving lysosomes) represents a significant off-target drug effect that could benefit from a well-
defined structure activity relationship.   
Many lysosomotropic drugs share a common structure feature in that they possess a region that is 
relatively hydrophobic and also have a cationic function group (weak base).  These drugs are generally 
referred to as cationic amphiphilic drugs or CADs.  Over the last six decades many of these drugs have 
been observed to cause an interesting biochemical and morphological anomaly referred to as 
phospholipidosis (PL) (Halliwell 1997, Lowe, Glen et al. 2010).  This condition is characterized by the 
hyper-accumulation of lipids and the appearance of lamellar inclusion bodies that are visible by electron 
microscopy (Yamamoto, Adachi et al. 1971, Anderson and Borlak 2006, Tomizawa, Sugano et al. 2006).  
In chapter 3 we detailed the relationship between the expanded LVP and phospholipidosis (PL).  We 
found that the ion trapping-independent mechanisms of drug uptake in cultured cells, i.e., lipid binding 
(Figure 3.8), exhibited a time-dependent increase which contributed to the enhanced cellular 
accumulation of lysosomotropic drugs.  Not surprising, many of the lysosomotropic drugs that we have 
identified as inducers of an expanded LVP (Figure 1.2, Figure 2.2) have also been shown to cause PL 
(e.g., chlorpromazine, imipramine, chloroquine, lidocaine, propranolol etc.) (Lowe, Glen et al. 2010).  
Previous reports have also implicated PL as a condition that can instigate a drug-drug interaction similar 
to what we have reported in chapters 2 and 3.  For example, Reasor and coworkers have shown that 
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alveolar macrophages isolated from rats pretreated with the phospholipidosis-inducing drug 
chlorphentermine can accumulate significantly more amiodarone than alveolar macrophages isolated 
from rats not pre-treated with chlorphentermine (Reasor 1991).  In addition, the phospholipidosis-
inducing drug chloroquine has also been shown to increase the cellular accumulation of secondarily 
administered lysotracker green, a lysosomotropic fluorescent probe similar to lysotracker red (Zheng, 
Zhang et al. 2011).  The exact contribution that PL plays in the total development of this drug-drug 
interaction is not currently known.  However, based on the work in chapters 2 and 3, we would reason 
that PL likely plays an important but not exclusive role in the development of the expanded LVP and the 
ensuing drug-drug interaction involving lysosomes.   
Irrespective of the exact contribution that PL plays in the development of the expanded LVP, we feel 
that a drug’s potential to cause PL and the expanded LVP represents an important consideration in the 
drug development process.  Consistent with this notion, the FDA considers drug-induced 
phospholipidosis to be a dubious off-target drug effect.  Regardless of the poorly established link 
between drug-induced PL and clinically significant adverse effects the FDA will frequently require 
additional toxicological studies to assuage safety concerns.  The FDA will also request long-term studies 
that show the reversibility of the observed drug-induced phenotype (Reasor, Hastings et al. 2006, 
Chatman, Morton et al. 2009).  These additional studies can be both resource and time intensive.  
Pharmaceutical scientists would therefore benefit from a system that could predict these off-target drug 
effects.  With this in mind, the focus of this chapter was to identify key structural features of 
lysosomotropic drugs that correlate with their potency in eliciting an expanded LVP which can also be 
expected to include phospholipidosis. 
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Materials and Methods 
Cell Lines and Reagents 
Wild-type (WT) human fibroblasts (catalogue # CRL-2076) were purchased from ATCC (Manassas, VA).  
All cells were cultured in glutamine-free DMEM supplemented with 10% FBS, 10mM HEPES, 1mM 
Sodium Pyruvate, and 2mM Glutamax and maintained at 37 degrees C and 5% CO2.  Cells were routinely 
subcultured to maintain 50% to 90% confluency.  Experiments were carried out within 10 passages 
following removal from cryopreservation. Dulbecco’s phosphate buffered saline (D-PBS), Dulbecco’s 
modified Eagle’s medium (DMEM), HEPES, sodium pyruvate, glutamax, and LysoTracker Red DND-99 
(LTR) were purchased from Invitrogen (Carlsbad, CA).  Fetal bovine serum (FBS) was purchased from 
Atlanta Biologicals (Lawrenceville, GA).  Halofantrine, propranolol, U18666A, lidocaine, imipramine, 
chloroquine, ammonium chloride, ibuprofen, cyclofenil, and all benzylamine derivatives were purchased 
from Sigma-Aldrich (St. Louis, MO).  (S)-naproxen was purchased from Cayman Chemical Company (Ann 
Arbor, MI).  Pierce BCA protein assay kit was ordered from ThermoScientific (Rockford, IL).  3[H]-
halofantrine and 3[H]-propranolol were purchased from American Radiolabeled Chemicals, Inc. (St. 
Louis, MO).  14[C]-methylamine was purchased from Moravek Biochemicals (Brea, CA).  NBD-PC was 
purchased from Avanti Polar Lipids (Alabaster, Alabama). 
LysoTracker Red accumulation assay 
WT human fibroblasts were grown in plastic 12-well culture plates (Corning Life Sciences) at a seeding 
density of approximately 75,000 cells per well.  Following a 48-hour pretreatment with various drugs 
(concentrations of each drug is stated in the figure legend), LysoTracker Red was spiked into the growth 
media to a concentration of 200nM and the cells were incubated for 1 hour.  Cells were then rapidly 
washed twice with 4 degrees C D-PBS.  Cells were lysed with lysis buffer (50 mM tris base, 150 mM NaCl, 
1% NP40, pH 7.4).  The quantity of LTR was determined by fluorescent signal in relative fluorescence 
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units (RFU) using a Bio-Tek FL600 microplate fluorescence reader.  Protein abundance was measured for 
each sample using the BCA method.  Measured LTR signal (RFU) was then normalized to protein.  These 
normalized values were then compared to the control condition (vehicle treated) and depicted as a 
percentage of the control.   
Cell imaging (NBD-PC cellular accumulation) 
All cell imaging was performed on a Nikon Eclipse 80i epifluorescence microscope equipped with a 20X 
phase contrast objective (Ph2).  All images were acquired on a Hamamatsu ORCA ER digital camera.  
Images were analyzed using Metamorph software version 7.0 (Universal Imaging) and ImageJ software 
(free online atrsbweb.nih.gov) software. WT human fibroblasts were grown on glass coverslips under 
the stated growth conditions for 2days.  24hrs prior to the cell imaging 40µM NBD-PC was spiked into 
the existing extracellular growth media of each sample.  At the end of the 24hr exposure to NBD-PC the 
coverslips were washed 3 times with ice-cold PBS and then mounted onto glass slides and imaged using 
the appropriate filter sets to match the spectral properties of NBD-PC.  All images were taken using 
identical lamp power and exposure times making the NBD-PC signal intensity directly comparable across 
all images. 
Red Blood Cell Hemolysis Assay 
Whole blood was obtained from a fasting 23 year old male volunteer via venipuncture.  The Red blood 
cells (RBC)s were then isolated using the procedure detailed by Reinhart and Chien (Reinhart and Chien 
1986).  Briefly, approximately 15mL of whole blood was drawn into a 25mL syringe.  The blood was then 
spiked with 20 units/mL heparin to prevent clotting.  The whole blood was centrifuged at 1,000g for 
15minutes which separated the whole blood into three fractions, RBCs, white blood cells, and plasma.  
After remove the top layers of plasma and white blood cells, the RBCs were washed three times by 
resuspended them in ice cold PBS using a 1:3 ratio, respectively.  The RBC/PBS mixture was then 
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centrifuged at 1,000g for 15minutes.  After the final wash, the RBCs were resuspended in ice cold PBS to 
an approximate hematocrit value of 10%.  1.6mL aliquots of these washed RBCs were then placed into 
2mL centrifuge tubes.  The aliquots were then pre-warmed to 37°C for 10 minutes.  Various drugs or 
vehicle alone were then spiked into the 1.6mL aliquots and incubated for 3 hours at 37°C.  Following the 
3hr incubation, the samples were centrifuged at 1,000g for 10minutes.  200µL of the supernatant was 
then carefully withdrawn and placed into a 96well plate.  Using a UV-plate reader the absorbance at 
545nm was then assessed which correlates to the abundance of hemoglobin. 
Determination of the percentage of RBCs that were hemolyzed was achieved by evaluating a RBC aliquot 
that was fully lysed, i.e., 100% of the RBCs were lysed.  Briefly, aliquots of RBCs were spiked with Triton 
X-100 to fully lyse all the cells present in the sample.  Following the same procedure used for the drug-
containing samples, the absorbance of the supernatant was then measured at 545nm.  After accounting 
for background and the linear range of the instrument, an apparent value was obtained that 
represented 100% RBC hemolysis.  All Abs 545nm values were than normalized to this apparent value to 
obtain a percentage of RBC hemolysis. 
Drug Accumulation Assays 
 
WT human fibroblasts were seeded into plastic 12-well culture plates at a seeding density of 90,000 cells 
per well overnight.  The extracellular media was then replaced with drug-containing media as stated in 
the figure legend.  In addition to the stated drug exposures all samples contained identical 
concentrations of tritium-labeled propranolol (5nM 3[H]-propranolol at .06µCi/mL).  Following a 2day 
exposure to these stated conditions, the cellular accumulation of tritium-labeled propranolol was then 
assessed.  Briefly, at the end of the two day drug-treatment the extracellular media was removed by 
aspiration and the cells were washed two times with ice-cold PBS.  The cells were then lysed in 250µL 
84 
 
lysis buffer for 30mins at 37°C.  The abundance of tritium labeled propranolol was then measured 
measured in decays per minute (DPM)s using a Beckman LS 60001C liquid scintillation counter.  
Background signal contributed from non-specific binding of drug to the plate surface was subtracted 
from each measurement.  Protein abundance was measured for each sample using the BCA method.  
The measured DPMs present in each sample was then normalized to µg of cellular protein. 
 
Results and Discussion 
Lysosomotropic properties greatly enhance a molecules ability to induce an expanded LVP 
After establishing the cellular mechanisms that contributed to the expanded LVP seen in cells treated 
with lysosomotropic drugs (chapters 2 and 3), we next sought to determine which physicochemical 
properties of these molecules correlated with their ability to induce this phenotype.  A typical approach 
to developing a structure activity relationship could include screening a chemical library containing 
thousands of molecules; however, due to the high expense of this strategy we decided to utilize a more 
targeted approach.  To this end, we first sought to evaluate how lysosomotropic properties could 
influence a molecule’s potency in eliciting this effect.  Although potency could refer to many biological 
processes we will hereby refer to potency in regard to a drug’s ability to induce an expanded LVP unless 
stated otherwise. 
In order to evaluate changes in the steady state volume of lysosomes we measured the influence that 
various drug exposures had on the cellular uptake of the fluorescent lysosomotropic probe lysotracker 
red (LTR) and then compared those values to the vehicle treated control.  Conditions that increased the 
cellular accumulation of LTR beyond 100% of control would be identified as an inducer of the expanded 
LVP.  Using this approach we evaluated the test compounds’ relative potencies by comparing the 
concentrations of compound necessary to elicit an expanded LVP. 
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U18666A is a well characterized lysosomotropic molecule that is known to perturb the lysosomal system 
(Amritraj, Peake et al. 2009, Poh, Shui et al. 2012).  In chapter 2 we detailed how U18666A could 
increase the steady state volume of lysosomes (Figure 2.2) and decrease vesicle-mediated trafficking out 
of the lysosomes (Figure 2.6).  Previous reports have also implicated progesterone as a molecule that 
could cause similar trafficking defects to those caused by U18666A (Butler, Blanchette-Mackie et al. 
1992, te Vruchte, Lloyd-Evans et al. 2004).  After establishing that both progesterone and U18666A 
could produce similar perturbations in the lysosomal system we then sought to evaluate their relative 
potencies in eliciting an expanded LVP.   
Although both progesterone and U18666A were both capable of causing an expanded LVP, U18666A 
was dramatically more potent (Figure 4.1).  Due to the structural similarities between their hydrophobic 
regions, we reasoned that the >10 fold increase in U18666A potency was likely attributed to its 
lysosomotropic properties.  We further sought to validate this assumption by comparing a different set 
of structurally similar molecules that differed only in their lysosomotropic properties.  The anesthetic 
drug lidocaine is well established as a lysosomotropic drug (Vandenbroucke-Grauls, Thijssen et al. 1984); 
however, its quaternary amine analog (lidocaine N-ethyl) would not be considered to be lysosomotropic 
due to its lack of an ionizable amine.  Consistent with our results comparing U18666A and progesterone, 
we found that lidocaine exhibited a >10 fold increase in its potency compared to its non-lysosomotropic 
quaternary amine analog (Figure 4.2).  Together, these results indicate that lysosomotropic properties 
can greatly enhance a molecule’s potency in eliciting an expanded LVP, and by extension a drug-drug 
interaction involving lysosomes. 
Although these examples are useful in establishing the influence that lysosomotropic properties have on 
a molecule’s potency, they have very little clinical relevance.  To our knowledge U18666A and the 
quaternary amine analog of lidocaine are not used as drugs in humans.  In an effort to provide a more 
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clinically relevant example we next sought to evaluate a wide range of drugs that did or did not possess 
lysosomotropic properties.  We chose a set of 7 different drugs, 4 that possessed lysosomotropic 
properties (e.g., chlorpromazine, imipramine, propranolol, and lidocaine) and 3 that did not possess 
lysosomotropic properties (e.g., naproxen, ibuprofen, and cycofenil) (Figure 4.3).  We found that all of 
the lysosomotropic drugs (labeled with dotted lines) were capable of causing an expanded LVP; 
however, all of the non-lysosomotropic drugs (labeled with solid lines) failed to cause an expanded LVP 
(Figure 4.3).  These results further strength the notion that lysosomotropic properties enhance a 
molecule’s ability to induce an expanded LVP. 
Lipophilicity alone does not correlate with a lysosomotropic molecule’s potency capacity to induce an 
expanded LVP 
After establishing that lysosomotropic properties greatly enhanced a molecules potency we next sought 
to determine how the lipophilicity of these molecules might also influence their potency.  We initially 
screen several different lysosomotropic molecules with a calculated Log P ranging from -0.6 to 2.5.  
Interestingly, we found that none of tested lysosomotropic molecules were capable of inducing an 
expanded LVP (Figure 4.4).  Surprised by these results, we further evaluated 4 FDA approved 
lysosomotropic drugs (erythromycin, azithromycin, propranolol, and lidocaine) that all possessed a 
calculated Log P of approximately 2.5 (Figure 4.5).  We reasoned that if the lipophilicity of these 
molecules was the primary physicochemical property that determined potency then all 4 of these drugs 
should have failed to produce an expanded LVP similar to that seen with triisopropylamine (Figure 4.4) 
that also possess a Log P of 2.5.  Instead, all 4 of the drugs in Figure 4.5 induced an expanded LVP.  These 
results indicated that the lipophilicity of lysosomotropic molecules alone did not determine their 
capacity to induce an expanded LVP. 
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In order to more deeply explore the relationship between a drug’s lipophilicity and its potency we also 
screened a large array of 17 different lysosomotropic drugs possessing a calculated Log P from 2.3 to 
7.9.  By performing a dose response curve for each drug, measuring LTR uptake versus drug 
concentrations, we were able to compare the relative potencies of each drug.  We found that the 17 
different drugs varied widely in their potencies.  To achieve a more uniform comparison of each drug’s 
potency, we extrapolated the concentration of each drug necessary to achieve a LTR uptake at 150% of 
control (EC150%).  To illustrate the relationship between potency and lipophilicity we then plotted those 
EC150% values against the corresponding drug’s calculated Log P (Figure 4.6).  Overall, we found that 
lipophilicity roughly correlated with a drug’s capacity to induce an expanded LVP; however, the weak 
correlation (r2= .497) indicated other physicochemical properties were likely involved in determining the 
overall potency of each drug. 
The aliphatic linkage between the hydrophilic and hydrophobic region of lysosomotropic molecules is 
proportional its potency in inducing an expanded LVP 
In an effort to pinpoint additional structural properties that might influence potency we reviewed the 
chemical structures present in Figure 4.5 and compared those to Figure 4.4.  We had reasoned that the 
structural differences present between these two sets of molecules would shed light on what key 
physicochemical properties might be influencing potency, i.e., one set of molecules caused an expanded 
LVP and one did not.  Based on our previous analysis we had already eliminated Log P as the primary 
factor that determined potency.  Upon visual inspection it was clear that the amphiphilic nature of the 
two sets of molecules were strikingly different.  Although methylamine and t-butylamine are 
amphiphilic, they lack a large separation between their hydrophilic and hydrophobic regions as opposed 
to propranolol and lidocaine that possess a relatively large separation between their hydrophobic region 
(aromatic rings) and their hydrophilic region (ionizable amine).  In order to explore this more thoroughly 
we sought to evaluate the potency of several benzylamine analogs that possessed a varying degree of 
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aliphatic linkage between the hydrophobic benzyl group and the hydrophilic primary amine (Figure 4.7).  
Interesting, we found that the aliphatic linkage greatly influenced the potency of these molecules.  
These results showed that as the length of the carbon linkage increased so too did the molecules ability 
to induce an expanded LVP indicating that the amphiphilic character of these molecules likely played an 
important role in determining their potencies. 
The aromatic bulk of a lysosomotropic molecule correlates with its potency in inducing an expanded 
LVP 
The result of the previous section was indicated that the amphiphilicity of these molecules is a key 
structural feature that influences potency.  With this in mind, we considered other characteristics of 
amphiphilicity, specifically the surface area of a molecule’s hydrophobic region.  Although the 
hydrophilic surface area of these molecules could conceivably be changed as well, these alterations 
would likely result in dramatically different electronic properties of the ionizable amine.  Ultimately 
these changes could modulate the pKa of the ionizable amine and influence the degree of ion trapping.  
In an effort to avoid tuning the pKa of the amine we instead focused our efforts on changing the surface 
area of the hydrophobic region.  
Similar to the approach used to assess aliphatic chain length, we again assessed analogs of benzylamine 
that possessed progressively greater degrees of aromatic bulk (Figure 4.8).  These results showed that 
the aromatic bulk of these molecules dramatically influenced their potency.  Each additional aromatic 
ring caused an approximate 10 fold increase in the molecules relative potency to compared to 
benzylamine. 
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The aliphatic chain length and aromatic bulk of a lysosomotropic molecule exhibit an additive 
influence on its potency to inducing an expanded LVP 
After establishing that the aliphatic chain length and the surface area of the hydrophobic region greatly 
influenced the potency of lysosomotropic molecules we next sought to evaluate how these two 
structural properties might influence potency in combination.  This was an important question to 
answer as the 17 different lysosomotropic drugs analyzed in the previous section (Figure 4.6) all 
exhibited varying combinations of these two structural features.  To address this question, we analyzed 
structural analogs of benzylamine that varied in both chain length and the number of aromatic rings 
(Figure 4.9).  These results show that increasing the aliphatic chain length from 1 carbon to 3 carbons 
imparts an increase to the molecule’s potency, as was seen in Figure 4.7.  However, if an additional 
aromatic ring is included on this same molecule its potency is significantly enhanced.  Overall, these 
results show that the total surface area of the hydrophobic region and the aliphatic linkage between this 
region and the hydrophobic region influence the potency of lysosomotropic molecules in an additive 
fashion. 
A lysosomotropic drug’s potency in eliciting an expanded LVP correlates with its capacity to 
intercalate into cellular membranes 
After observing that 17 different lysosomotropic drugs were capable of causing an expanded LVP, we 
began to reason that their ability to induce this effect was likely the result of some nonspecific drug 
interaction/effect.  Previous work has shown that many of these 17 drugs (chlorpromazine, imipramine, 
propranolol etc.) were capable of intercalating into biological membranes (Zachowski and Durand 1988, 
Reinhart and Rohner 1990, Maruoka, Murata et al. 2007).  Others have shown that drugs intercalating 
into biological membranes can lead to changes in membrane fluidity, integral membrane protein 
activity, and alterations in vesicle-mediated trafficking, all of which are consistent with our observations 
detailed in the previous chapters (Spinedi, Pacini et al. 1989, Maruoka, Murata et al. 2007, Suwalsky, 
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Villena et al. 2008).  With this in mind, we reasoned that these drugs could be causing the formation of 
an expanded LVP by intercalating into the lysosomal membranes.   
In order to test this hypothesis we narrowed our analysis down to 5 different lysosomotropic molecules 
that showed a varying degree of potency from low (methylamine) to high (chlorpromazine) (Figure 
4.10).  We then sought to measure their capacity to intercalate into a biological membrane.  If our 
hypothesis was correct we had expected to see that the same rank-order in potency for both their 
ability to cause an expanded LVP and their ability to intercalate into membranes. 
Over the past few decades red blood cells (RBCs) have been extensively used to measure membrane 
intercalation of a wide array of different drugs.  Due to the robust body of published work, accessibility, 
and ease of isolation we employed a RBC hemolysis assay to measure a molecules capacity to intercalate 
into membranes.  The basis for the RBC hemolysis assay is that the RBC plasma membrane becomes 
increasing destabilized as more drug molecules become intercalated into it.  Initially the drug 
intercalation leads to morphological changes in the membranes of RBCs producing spikey membrane-
protrusions and conical shaped membrane-invaginations that are visible by light microscopy.  After 
reaching some unknown threshold of destabilization, the RBC plasma membrane becomes perforated 
resulting in the spillage of the RBC contents into the extracellular environment.  The extracellular 
environment can then be assayed for RBC content, e.g., hemoglobin which has a high absorbance at 
545nm (Isomaa, Hagerstrand et al. 1986, Reinhart and Chien 1986, Fujiwara, Hirashima et al. 2001).   
Using this approach we measured the percentage of RBC hemolysis over a wide range of test molecule 
concentrations from low micromolar to high millimolar (Figure 4.11).  These results indicated that 
chlorpromazine possessed the greatest capacity to cause RBC hemolysis while ammonium chloride 
showed an inability to cause RBC hemolysis up to a 1M concentration.  Interestingly, both Figure 4.11 
and Figure 4.10 showed the same order of potencies: chlorpromazine> imipramine> propranolol> 
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lidocaine> ammonium chloride.  These results indicate that membrane intercalation is likely one of the 
primary mechanisms underlying the development of the expanded LVP. 
Low concentrations of lysosomotropic drugs can work in a concerted fashion to cause an expanded 
LVP 
The results of the previous section lead us to believe that drugs causing an expanded LVP were not 
involved in a specific drug-protein or drug-receptor interaction that mediated some down-stream 
physiological response, but rather, these drugs were acting in a non-specific manner by simply 
intercalating into the lysosomal membrane and possibly disrupting normal lysosome function.  In 
support of this notion, previous reports have detailed how drug intercalation into biological membranes 
can alter membrane charge and fluidity and perturb a range of physiological functions such as vesicle-
mediated trafficking and enzyme activity  (Spinedi, Pacini et al. 1989, Kolzer, Werth et al. 2004, 
Maruoka, Murata et al. 2007, Suwalsky, Villena et al. 2008).   
To investigate this hypothesis in more detail we next evaluated the capacity of these drugs to work in a 
concerted fashion to bring about an expanded LVP.  We reasoned that if these drugs were causing this 
phenotype in a non-specific manner, simply by intercalating into membranes, then combinations of 
these drugs should be additive in their ability to perturb lysosome function and by extension increase 
lysosomal volume.  To this end, we first visually inspected the dose responses for 7 different 
lysosomotropic drugs (drug concentration versus LTR uptake) and identified the highest concentration 
of drug that was unable to produce an expanded LVP.  For example, in Figure 4.10 propranolol begins to 
induce an expanded LVP phenotype at a concentration of approximately 500nM and higher.  
Concentrations below 500nM should therefore not produce an expanded LVP.  We repeated this 
process and identified a threshold concentration for 7 different lysosomotropic drugs.  These values 
ranged from low nanomolar to high nanomolar depending on the potency of the lysosomotropic drug.   
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To test our hypothesis we treated cells with only one drug at a concentration that was just below its 
threshold for inducing an expanded LVP.  In parallel to these individual exposures we also treated cells 
with a combination of all 7 drugs at those same concentrations (Figure 4.12 A).  Consistent with our 
expectations we found that the drugs were unable to cause an expanded LVP at concentrations below 
the previously identified threshold; however, when all 7 drugs were combined together we observed 
that the drugs did induce an expanded LVP.  This result supported our hypothesis that these drugs might 
be interacting with membranes in a non-specific manner. 
Although LTR is a well-established lysosomotropic probe, it is technically not considered a drug.  In order 
to provide a more clinically relevant example of this phenomenon we repeated this experiment but 
instead of measuring LTR cellular uptake we measured the uptake of tritium labeled propranolol (Figure 
4.12 B).  This experiment was meant to mimic an in vivo scenario where an individual might be exposed 
to very low concentrations of multiple lysosomotropic amphiphiles (either endogenous amphiphiles or 
xenobiotic amphiphiles) thereby resulting in a drug-drug interaction involving lysosomes where the 
perpetrator drugs was actually an array of drugs rather than a single drug.  The results of this 
experiment showed that multiple drugs could work in concert to produce a drug-drug interaction 
involving lysosomes that results in the enhanced cellular accumulation of a victim drug (propranolol). 
Low concentrations of lysosomotropic drugs can work in an additive manner to cause lipid trafficking 
defects 
In previous chapters we showed that impaired vesicle-mediated trafficking was observed in cells treated 
with lysosomotropic drugs (Figure 2.6); however, these assessments were performed using drug 
concentrations that were above the threshold for causing an expanded LVP.  For example, cells exposed 
to concentrations of propranolol above 500nM for 2 days will result in the formation of an expanded 
LVP.  The dextran release data illustrated in Figure 2.6 was obtained from cells exposed to 4µM 
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propranolol for 2 days which is well above the “threshold concentration”.  In this section we have sought 
to determine if multiple lysosomotropic drugs, at concentrations below their respective threshold 
concentrations, could work in concert as was illustrated in Figure 4.12 to cause a lipid trafficking defect.  
We reasoned that the lipid transport efficiency of cells should be unimpaired when exposed to 
lysosomotropic drugs that are below their respective threshold concentration but when cells are 
exposed to a combination of all these drugs they will exhibit a lipid trafficking defect. 
To evaluate this question we employed the use of nitrobenzoxadiazole-phosphotidylcholine (NBD-PC) a 
fluorescently labeled phospholipid.  NBD-PC is frequently used to assess the efficiency of phospholipid 
transport within cells (Kasahara, Tomita et al. 2006).  The rational for this assay is that the total cellular 
accumulation of NBD-PC will be determined by the rate of NBD-PC uptake versus the rate of NBD-PC 
release from the cells.  If cells are exposed to condition that reduce the efficiency of lipid transport then 
the cells would be expected to accumulate a greater amount of NBD-PC.  The total NBD-PC fluorescence 
can therefore be used as a surrogate marker for the efficiency of lipid transport, i.e., greater amounts of 
NBD-PC fluorescence indicates reduced lipid transport efficiency. 
Using the same protocol detailed for the experiments in Figure 4.12, we repeated the experiment but 
instead of measuring LTR uptake or tritium labeled propranolol we measured the cellular accumulation 
of NBD-PC by fluorescence microscopy (Figure 4.13).  In support of our hypothesis, we found that cells 
exposed to lysosomotropic drugs at concentrations below their respective “threshold” accumulated 
similar amounts of NBD-PC as compared to control, i.e., the intracellular green fluorescence was similar 
in intensity between the cells treated with vehicle (control) and cells treated with a single drug.  
However; when cells were exposed to a combination of all 7 drugs at those same concentrations, the 
cells exhibited a substantially greater NBD-PC fluorescence. 
94 
 
Conclusion 
In cultured human cells we have found that lysosomotropic drugs are capable of causing a significant 
expansion in the steady state volume of lysosomes.  In the previous chapters we detailed how this 
expansion in lysosomal volume can lead to a drug-drug interaction resulting in the enhanced cellular 
accumulation of secondarily administered lysosomotropic drugs.  We have further detailed the potential 
clinical ramifications of this phenomenon by predicting how these changes might influence whole-body 
pharmacokinetic proprieties, specifically the volume of distribution and half-life.  With this in mind we 
consider the drug-induced expansion of lysosomal volume to be a significant off-target drug effect that 
could benefit from a well-characterized structure activity relationship. 
Although a structure activity relationship is currently not established for lysosomotropic drugs and their 
ability to induce an expanded LVP, others have made attempts to predict a similar drug-induced 
phenomenon termed phospholipidosis (PL).  In chapter 3 we detailed the relationship between the 
expanded LVP and PL.  We found that many of the lysosomotropic drugs that caused an expansion in 
lysosomal volume have also been shown to induce PL (Lowe, Glen et al. 2010).  Based on our data 
however, we would conclude that PL accounts for only a portion of these cells’ enhanced capacity to 
accumulate lysosomotropic drugs.  We feel that the “expanded LVP” is a much broader phenotypic 
descriptor that includes both changes to phospholipid bindings sites (i.e., phosopholipidosis) and 
changes to the aqueous volume of lysosomes.  We would therefore reason that measuring changes to 
the steady state volume of lysosomes, using LTR uptake or a similar approach, is a much more inclusive 
screening criteria rather than analyzing tissue samples for hallmark signs of PL which can pose great 
variability and inconsistent results.  The hallmark sign of PL, i.e., multi-lamellar bodies/membrane 
whorls/myeloid bodies, can be present in some tissues while absent in others (Reasor, Hastings et al. 
2006, Tengstrand, Miwa et al. 2010).  Signs of drug-induced phospholipidosis can also exhibit a high 
degree of variability within a single species and between different species (Halliwell 1997, Chatman, 
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Morton et al. 2009).  For example, the FDA’s Phospholipidosis Working Group has shown that certain 
drugs can cause signs of PL in certain animal models but not in humans and vice-versa. 
In an effort to establish a structure activity relationship for the development of the expanded LVP we 
first reviewed the physicochemical properties of drugs that were previously implicated in the 
development of drug-induced PL.  Although drug-induced PL is difficult to predict and likely only 
accounts for a portion of a cell’s total enhanced drug-accumulation capacity we felt that these two 
conditions would likely share a very similar structure activity relationship.  Over the last decade many 
models have been developed to predict drug-induced PL.  Ploemen and coworkders have developed the 
most simple model that predicts phospholipidosis inducing compounds as those that have a pKa greater 
than 8 and a Log P greater than 1 while also satisfying the following criteria (calculated Log P)2 + 
(calculated pKa)2 > 90.  Many additional models have been developed that incorporate machine learning 
and complex statistical methodologies but the overall success of these more complex models in 
predicting PL is only marginally better than the model developed by Ploemen and coworker (Lowe, Glen 
et al. 2010).  We therefore focused our attention on the parameters of the simple model which included 
pKa and Log P.  We reasoned that the pKa would likely be important due to its influence on a drugs 
potential to be entrapped into lysosomes by ion trapping (Ndolo, Forrest et al. 2010, Ndolo, Jacobs et al. 
2010). The Log P would likely influence parameters such as cell permeability and the degree of 
membrane intercalation.  
Due to the high cost of developing and running a high throughput assay that can screen thousands of 
molecules, we employed a more targeted approach and rationally chose specific physicochemical 
properties that might influence a molecules potency in cause an expanded LVP (referred to hereafter as 
just potency).  We then designed a battery of molecules that would allow us to interrogate how those 
specific physicochemical properties related to a molecule’s potency. 
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We initially evaluated the influence that lysosomotropic properties had on potency by analyzing two 
sets of structurally similar molecules (lidocaine vs. lidocaine N-ethyl and U18666A vs. progesterone).  
We had previously shown that the lysosomotropic drug lidocaine was capable of causing an expanded 
LVP (Figure 2.2).  In order to test how its lysosomotropic properties contributed to its potency we tested 
its quaternary amine analog (lidocaine N-ethyl) which is not considered to be lysosomotropic due to its 
lack of an ionizable amine (Figure 4.2).  The results of this experiment showed that the lysosomotropic 
properties of lidocaine imparted a >10fold increase to its potency.   
In chapter 2 we had also established that the lysosomotropic molecule U18666A was capable of eliciting 
an expanded LVP (Figure 2.2).  In order to test the contribution that lysosomotropic properties were 
imparting on U18666A we performed a comparative analysis of U18666A versus progesterone (Figure 
4.1).  These two molecules possess structurally similar hydrophobic regions; however, progesterone is 
considered to be non-lysosomotropic due to its lack of an ionizable amine.  Similar to the results 
obtained with lidocaine, we found that the lysosomotropic properties of U18666A also imparted a 
>10fold increase to its potency. 
After establishing the strong influence that lysosomotropic properties had on molecules’ potency, we 
next sought to determine other physicochemical properties that might also modulate their ability to 
induce an expanded LVP.  Based on the model developed by Poloeman and coworkers we reasoned that 
lipophilicity might also play an important role in determining the potency of lysosomotropic molecules.   
A review of data presented in Figure 4.2 showing that lidocaine was capable of inducing an expanded 
LVP lead us to hypothesis that lysosomotropic molecules with a Log P of approximately 2.4 should be 
capable of expanding lysosomal volume; however, we did not know if molecules must possess a 
minimum lipophilic character in order to induce an expanded LVP.  To answer this question we 
evaluated a set of lysosomotropic molecules possess a calculated Log P ranging from -0.6 to 2.5 (Figure 
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4.4).  Interestingly, we found that all of these molecules failed to cause an expanded LVP.  Surprised by 
these results, we further investigated 4 FDA approved drugs that all possessed a Log P of approximately 
2.4 (Figure 4.5).  We found that all 4 of these drugs were capable of causing an expanded LVP.  These 
results indicated that lipophilicity alone did not determine the potency of these lysosomotropic 
molecules. 
To further confirm these results and more thoroughly evaluate the influence that lipophilicity plays in 
determining potency we expanded our analysis to include a wide array of 17 different lysosomotropic 
drugs that possessed a calculated Log P ranging from 2.32 to 7.93 (Figure 4.6).  In order to achieve a 
uniform analysis of potency across these 17 different lysosomotropic drugs we performed a dose 
response for each drug measuring LTR uptake versus drug concentration.  From these dose responses 
we extrapolated the concentration of drug necessary to achieve a LTR uptake of 150% of control 
(EC150%).  The array of data illustrated in Figure 4.6 showed a very poor correlation between lipophilicity 
and potency (r2=.497) which confirmed our initial assessment. 
These results lead us to investigate other structural features that might influence their potency.  By 
reviewing the structures in Figure 4.4 and comparing those to Figure 4.5 we began to recognize that 
molecules capable of causing an expanded LVP tended to have strong amphiphilic characteristics.  For 
example, lidocaine and propranolol possess a hydrophobic ring structure and a weakly basic amine that 
are separated by a linker of several atoms whereas the molecules incapable of causing an expanded LVP 
possessed only one carbon between their hydrophobic and hydrophilic regions.  The difference in 
potency observed between lidocaine and propranolol is also interesting to note.  Propranolol exhibited a 
>10 fold increase in its potency (EC150%) versus lidocaine.  We reasoned that propranolol was more 
potent because of its larger hydrophobic moiety (two aromatic rings versus lidocaine’s single aromatic 
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ring) even though their calculated Log Ps were strikingly similar.  With this in mind we next sought to 
specifically evaluate the influence that amphiphilicity had on the potency of lysosomotropic molecules. 
In order to test how amphiphilicity influenced potency we employed the use of benzylamine and several 
of its structural analogs.  We first explored the influence that the aliphatic linkage between the 
hydrophobic moiety and hydrophilic amine had on potency (Figure 4.7).  We found that as the linkage 
between the benzyl group and the amine increased, so too did the molecules potency.  We also 
examined how the size of the hydrophobic moiety could influence potency (Figure 4.8).  Consistent with 
the potency difference between propranolol to lidocaine, increasing the aromatic bulk of the 
benzylamine analogs caused a concomitant increase in their potency.  Intrigued by these results, we 
then sought to determine if these two structural features of amphiphilicity, i.e., aliphatic chain length 
and aromatic bulk, could work in an additive manner to increase a molecules overall potency (Figure 
4.9).  Interestingly, we found that these two features were additive in their ability to influence these 
potency.  This led us to conclude that the amphiphilic character of lysosomotropic molecules must be 
evaluated in order to predict its potential to cause an expanded LVP. 
After learning that the amphiphilic characteristics of these lysosomotropic molecules played an 
important role in determine their potency, we next began to speculate on why this feature was so 
important.  Although it was possible that these molecules were acting in a specific drug-protein or drug-
receptor interaction, we did not consider this possibility to be likely.  Due to the high specificity of 
protein-ligand interactions we found it implausible that a wide array of structurally diverse drugs could 
all be interacting with the same protein which ultimately lead to the development of the expanded LVP.  
We therefore considered the possibility that these drugs were interacting with the lysosomal 
membrane.  In support of this notion, previous reports have detailed how drug intercalation into 
biological membranes can perturb a range of physiological functions such as vesicle-mediated trafficking 
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and enzyme activity  (Spinedi, Pacini et al. 1989, Kolzer, Werth et al. 2004, Maruoka, Murata et al. 2007, 
Suwalsky, Villena et al. 2008); however, none of these reports correlated this interaction with the 
development of the expanded LVP. To further investigate the potential relationship between a 
molecule’s membrane intercalation potential and its potency in causing an expanded LVP we performed 
a comparative analysis relating each molecules’ potency (Figure 4.10) with its capacity to intercalate into 
a biological membrane (Figure 4.11).  The results of these experiments showed that the relative 
membrane intercalation potential of lysosomotropic molecules closely parallels their potency in causing 
an expanded LVP. 
To more fully develop the membrane-intercalation hypothesis we evaluated the ability of 
lysosomotropic drugs’ to work in a concerted fashion to bring about an expanded LVP.  We reasoned 
that if these drugs acted in a non-specific manner by intercalating into the lysosomal membrane then 
combinations of these drugs at low concentrations should be capable of eliciting the same effect as a 
single drug at a higher concentration.  In support of this hypothesis we found that these drugs elicited 
this additive effect in both their ability to increase lysosomal volume (Figure 4.12 A) and their ability to 
induce a drug-drug interaction involving lysosomes (Figure 4.12 B).  In addition, these drugs could also 
work in a concerted fashion to cause lipid trafficking defects (Figure 4.13).  These studies help to 
illustrate a proof-of-principle for how a drug-drug interaction could occur in vivo whereby the peripheral 
tissues of an individual exposed to several different amphiphilic molecules (either endogenous 
amphiphiles or xenobiotic amphiphiles) would exhibit an expanded LVP.  
The studies in this chapter have provided a foundation for a structure activity relationship that relates 
key physicochemical properties of lysosomotropic molecules with their ability to cause an expanded 
LVP, and by extension a drug-drug interaction involving lysosomes.  These studies have also provided 
the mechanistic basis for why different lysosomotropic molecules exhibit varying degrees of potency.  
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Overall the information presented in this section can potentially be used to instruct individuals on what 
key physicochemical properties of drugs might lead to a drug-drug interaction involving lysosomes. 
  
101 
 
 
 
Figure 4.1  Concentration-dependent cellular accumulation of LTR (200 nM for 1 hour) in wild-type 
human fibroblasts with a 48-hour pretreatment of various lysosomotropic molecules.  The reported 
values represent the average of approximately 500,000 cells.  Cellular accumulation of LTR was 
measured in fluorescence units and then normalized to cellular protein.  The normalized LTR uptake was 
then compared to the control condition (vehicle alone) and reported as a percentage of the control.  
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Figure 4.2  Concentration-dependent cellular accumulation of LTR (200 nM for 1 hour) in wild-type 
human fibroblasts with a 48-hour pretreatment of various lysosomotropic molecules.  The reported 
values represent the average of approximately 500,000 cells.  Cellular accumulation of LTR was 
measured in relative fluorescence units (RFU) and then normalized to cellular protein.  The normalized 
LTR uptake was then compared to the control condition (vehicle alone) and reported as a percentage of 
the control. 
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Figure 4.3  Concentration-dependent cellular accumulation of LTR (200 nM for 1 hour) in wild-type 
human fibroblasts with a 48-hour pretreatment of various drugs.  The black symbols with dotted lines all 
represent lysosomotropic drugs while the grey symbols with solid lines represent non-lysosomotropic 
drugs.  The reported values represent the average of approximately 500,000 cells.  Cellular accumulation 
of LTR was measured in fluorescence units and then normalized to cellular protein.  The normalized LTR 
uptake was then compared to the control condition (vehicle alone) and reported as a percentage of the 
control. 
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Figure 4.4  Concentration-dependent cellular accumulation of LTR (200 nM for 1 hour) in wild-type 
human fibroblasts with a 48-hour pretreatment of various lysosomotropic molecules.  The reported 
values represent the average of approximately 500,000 cells.  Cellular accumulation of LTR was 
measured in fluorescence units and then normalized to cellular protein.  The normalized LTR uptake was 
then compared to the control condition (vehicle alone) and reported as a percentage of the control. 
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Figure 4.5  Concentration-dependent cellular accumulation of LTR (200 nM for 1 hour) in wild-type 
human fibroblasts with a 48-hour pretreatment of various lysosomotropic molecules.  The reported 
values represent the average of approximately 500,000 cells.  Cellular accumulation of LTR was 
measured in fluorescence units and then normalized to cellular protein.  The normalized LTR uptake was 
then compared to the control condition (vehicle alone) and reported as a percentage of the control. 
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Figure 4.6  Correlation plot showing the relationship between of 17 different lysosomotropic drugs’ 
potency to induce an expanded LVP (EC150%) and their respective lipophilicity (Log P).  The (EC150%) was 
determined by performing a dose-response for each lysosomotropic drug, measuring LTR uptake versus 
drug concentration, and then extrapolating the concentration of drug necessary to achieve a LTR uptake 
of 150% of control.  The Log P was calculated using MarvinSketch (software freely available at 
chemaxon.com).  The following lysosomotropic drugs were assessed: U18666A, halofantrine, endoxifen, 
tamoxifen, chlorpromazine, quinacrine, raloxifene, amiodarone, haloperidol, imipramine, Y-134, 
propranolol, bupivacaine, chloroquine, lidocaine, erythromycin, and azithromycin. 
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Figure 4.7  Concentration-dependent cellular accumulation of LTR (200 nM for 1 hour) in wild-type 
human fibroblasts with a 48-hour pretreatment of various lysosomotropic molecules.  The reported 
values represent the average of approximately 500,000 cells.  Cellular accumulation of LTR was 
measured in fluorescence units and then normalized to cellular protein.  The normalized LTR uptake was 
then compared to the control condition (vehicle alone) and reported as a percentage of the control. 
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Figure 4.8  Concentration-dependent cellular accumulation of LTR (200 nM for 1 hour) in wild-type 
human fibroblasts with a 48-hour pretreatment of various lysosomotropic molecules.  The reported 
values represent the average of approximately 500,000 cells.  Cellular accumulation of LTR was 
measured in fluorescence units and then normalized to cellular protein.  The normalized LTR uptake was 
then compared to the control condition (vehicle alone) and reported as a percentage of the control. 
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Figure 4.9  Concentration-dependent cellular accumulation of LTR (200 nM for 1 hour) in wild-type 
human fibroblasts with a 48-hour pretreatment of various lysosomotropic molecules.  The reported 
values represent the average of approximately 500,000 cells.  Cellular accumulation of LTR was 
measured in fluorescence units and then normalized to cellular protein.  The normalized LTR uptake was 
then compared to the control condition (vehicle alone) and reported as a percentage of the control. 
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Figure 4.10  Concentration-dependent cellular accumulation of LTR (200 nM for 1 hour) in wild-type 
human fibroblasts with a 48-hour pretreatment of various lysosomotropic molecules.  The reported 
values represent the average of approximately 500,000 cells.  Cellular accumulation of LTR was 
measured in fluorescence units and then normalized to cellular protein.  The normalized LTR uptake was 
then compared to the control condition (vehicle alone) and reported as a percentage of the control. 
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Figure 4.11  Concentration-dependent drug-induced hemolysis of human red blood cells (RBC).  RBCs 
were isolated from whole blood and analyzed within 24hrs.  RBCs were exposed to various 
concentrations of lysosomotropic drugs for 3hrs at 37°C.  The extracellular release of hemoglobin was 
then analyzed by measuring the absorbance at 545nm.  The reported values represent the percentage of 
RBCs in the sample that was hemolyzed due to drug exposure.  The data illustrated in this graph was 
derived from an average of 3 to 4 independent experiments. 
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Figure 4.12  Lysosomotropic drugs affect lysosomes in an additive manner.  Cells were exposed to the 
indicated drug or combination of drugs for 48 hours.  After the 48hr drug treatment the cellular 
accumulation of (A) LTR or (B) tritium-labeled propranolol was measured.  The following drug 
concentrations were used in both (A) and (B) individually or in combination: amiodarone 215nM, 
chlorpromazine 30nM, halofantrine 100nM, imipramine 30nM, lidocaine 800nM, propranolol 450nM, 
haloperidol 430nM.   
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Figure 4.13  Lysosomotropic drugs affect lipid transport in an additive manner.  Cells were exposed to 
the indicated drug or combination of drugs for 48 hours.  24hrs prior to cell imaging NBD-PC was spiked 
into the existing cell culture media to a concentration of 40µM.  At the end of the 48hr drug exposure 
the cells were imaged using identical lamp power and exposure times.  The green signal represents NBD-
PC fluorescence while the blue signal (circular shapes) represent individual cell nuclei.  Each image 
contains approximately 6 to 12 cells.  The following drug concentrations were used in both (A) and (B) 
individually or in combination: amiodarone 215nM, chlorpromazine 30nM, halofantrine 100nM, 
imipramine 30nM, lidocaine 800nM, propranolol 450nM, haloperidol 430nM.    
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Chapter 5.  Studies on the influence that amphiphilic phenols have on the steady-state volume of 
lysosomes 
Introduction 
Lysosomal storage diseases (LSD)s are a set of inheritable diseases that occur when an individual harbors 
a functional mutation in a lysosome associated protein that leads to impaired catabolic activity of 
lysosomes.  This impaired catabolic activity can result in the buildup of metabolic substrates or 
undegraded material within the cells leading to additional downstream effects and toxicity (Kolter and 
Sandhoff 2010).  Overall, these diseases present in the human population at a relatively high frequency 
at 1 in 8,000 live births (Jeyakumar, Dwek et al. 2005).  Although there are approximately 40-50 known 
LSDs that are identified by mutations in unique proteins, these diseases can surprisingly share similar 
features including onset at a very early age and involvement of brain pathology.  In the previous 
chapters we have primarily focused on the drug-induced expansion of lysosomal volume and the 
ensuing changes to cellular physiology seen after treating cultured cells with lysosomotropic drugs.  
Interestingly, LSDs can also present a similar biochemical and morphological phenotype to that seen in 
cells treated with lysosomotropic drugs.  We and others have observed that LSDs also exhibit an 
expanded lysosomal volume phenotype (Figure 5.1) (Karageorgos, Isaac et al. 1997, Kolter and Sandhoff 
2010, Xu, Liu et al. 2012), an impaired rate of vesicle-mediated lysosomal egress (Goldman, Funk et al. 
2009), and the presentation of multilamellar bodies (lipid laden lysosomes) (Jeyakumar, Dwek et al. 
2005).  The similarity between LSDs, especially Niemann-Pick Type C Disease (NPC) (Matsuzawa, 
Yamamoto et al. 1977, Anderson and Borlak 2006), and drug-induced lysosomal dysfunction has also 
been recognized by the FDA and resulted in the formation of a special advisory board (Phosphoplipidosis 
Working Group) to more thoroughly explore this relationship (Reasor, Hastings et al. 2006, Tengstrand, 
Miwa et al. 2010). 
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Both LSDs and drug-induced changes to lysosomal function have been reported to cause severe toxic 
effects and even death (Honegger, Scuntaro et al. 1995, Futerman and van Meer 2004, Jeyakumar, Dwek 
et al. 2005).  Unfortunately, there are currently no FDA approved treatments for the brain pathologies 
caused by LSDs (Jeyakumar, Dwek et al. 2005) or treatment strategies to mitigate drug-induced 
dysfunction of lysosomes.  With this in mind we have focused the efforts of the current chapter on 
exploring treatment strategies that can help recover a normal lysosome phenotype in both the 
lysosomotropic drug-induced model and the LSD model.  Although these two models both present 
complex and multi-component impairments, we reasoned that lysosome dysfunction ultimately 
manifests itself as an expansion in lysosomal volume.  For this reason we have used lysosomal volume 
measurements (lysotracker red (LTR) uptake) as a surrogate marker for lysosome function. 
Within the last few years many reports have detailed the promising results that vitamin E has shown in 
its capacity to improve lysosome function and mitigate the ensuing toxicities seen with lysosome 
dysfunction.  For example, Arai and Coworkers have shown that the normal homeostatic balance of 
vitamin E plays an important role in reducing the severe cytotoxic effects of the lysosomotropic drug 
chloroquine in rat hepatoma cells (Shichiri, Kono et al. 2012).  Wiesmann and Coworkers have also 
shown that cultured human cells treated with 50µM α-tocopherol, one of the eight isomeric molecules 
that are collectively referred to as vitamin E (Figure 5.2) (Wang and Quinn 1999), exhibit a remarkable 
recovery in amiodarone-induced lysosome dysfunction (Honegger, Scuntaro et al. 1995).  Additionally, 
vitamin E has also been shown to improve lysosome-dysfunction in LSD models.  Xu et. al. has very 
recently reported on the capacity of δ-tocopherol (another of the eight isoforms of vitamin E) to 
improve cholesterol transport, reduce the hyperaccumulation of lipids, and recover lysosomal volume in 
NPC diseased human fibroblasts (Xu, Liu et al. 2012). 
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Although vitamin E shows great promise in its potential to be used as a treatment strategy to mitigate 
lysosomotropic drug toxicity and ameliorate the ill effects of LSDs, vitamin E is recognized as a poor 
drug-like molecule.  In addition to its very poor aqueous solubility, vitamin E has is also very prone to 
oxidation (Wang and Quinn 1999) and P450 enzyme metabolism by CYP4F2 (particularly δ-tocopherol) 
(Xu, Liu et al. 2012).  With this in mind, we sought to answer two main questions.  First, what changes 
are occurring to lysosomes after the administration of vitamin E.  And secondly, what physicochemical 
property of vitamin E is responsible for its activity.  We reasoned that if we could understand how 
vitamin E is influencing lysosomes and what structural feature of vitamin E is responsible for its activity 
then we could rationally design a drug that is capable of treating lysosome-dysfunction in either a drug-
induced scenario or in LSDs. 
Materials and Methods 
Cell Lines and Reagents 
Wild-type (WT) human fibroblasts (catalogue # CRL-2076), Niemann-Pick Type C1 (NPC1) diseased 
fibroblast, Niemann-Pick Type C2 (NPC2) diseased fibroblast, Niemann-Pick Type A (NPA) diseased 
fibroblast, and Sandhoff diseased fibroblast were all purchased from ATCC (Manassas, VA).  All cells 
were cultured in glutamine-free DMEM supplemented with 10% FBS, 10mM HEPES, 1mM Sodium 
Pyruvate, and 2mM Glutamax and maintained at 37 degrees C and 5% CO 2.  Cells were routinely 
subcultured to maintain 50% to 90% confluency.  Experiments were carried out within 10 passages 
following removal from cryopreservation. Dulbecco’s phosphate buffered saline (D-PBS), Dulbecco’s 
modified Eagle’s medium (DMEM), HEPES, sodium pyruvate, glutamax, Hoechst stain, and LysoTracker 
Red DND-99 (LTR) were purchased from Invitrogen (Carlsbad, CA).  Fetal bovine serum (FBS) was 
purchased from Atlanta Biologicals (Lawrenceville, GA).  Halofantrine, propranolol, verapamil, Laemmli 
buffer, and sodium deoxycholate were purchased from Sigma-Aldrich (St. Louis, MO).  Pierce BCA 
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protein assay kit was ordered from ThermoScientific (Rockford, IL).  Anti-p-glycoprotein primary 
antibody was a generous gift from Dr. Micheal Wang (Pharmaceutical Chemistry Department, University 
of Kansas, Lawrence, KS).  Anti-beta actin antibody (catalogue #8H10D10) was purchased from Cell 
Signaling Technology (Danvers, MA).  3[H]-halofantrine, and 3[H]-propranolol were purchased from 
American Radiolabeled Chemicals, Inc. (St. Louis, MO).   
LysoTracker Red accumulation assay 
Various human fibroblast cell lines were grown in plastic 12-well culture plates (Corning Life Sciences) at 
a seeding density of approximately 75,000 cells per well.  Following pretreatments with various drugs 
(concentrations and durations for each drug is stated in the figure legend), LysoTracker Red was spiked 
into the growth media to a concentration of 200nM and the cells were incubated for 1 hour.  Cells were 
then rapidly washed twice with 4 degrees C D-PBS.  Cells were lysed with lysis buffer (50 mM tris base, 
150 mM NaCl, 1% NP40, pH 7.4).  The quantity of LTR was determined by fluorescent signal in relative 
fluorescence units (RFU) using a Bio-Tek FL600 microplate fluorescence reader.  Protein abundance was 
measured for each sample using the BCA method.  Measured LTR signal (RFU) was then normalized to 
protein.  These normalized values were then compared to the control condition (vehicle treated) and 
depicted as a percentage of the control.   
Drug Accumulation Assays 
WT human fibroblasts were seeded and grown in plastic 12-well culture plates (Corning Life Sciences).  
On the following day the extracellular media was replaced with test media as stated in each figure 
legend.  The extracellular media was refreshed every 48hrs (sustaining the test condition) to maintain 
optimal growth conditions.  To assess the total drug accumulation at the end of the experiments the 
cells were immediately washed twice with 4°C D-PBS.  To assess the drug uptake by ion-trapping 
independent mechanisms, nigericin and monensin was spiked directly into the existing cell culture 
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media (final concentration of 10µM and 20µM, respectively) 2 hrs prior to reaching the desire drug 
exposure duration.  Once the desire drug exposure time was achieved, the cells were then washed twice 
with 4°C D-PBS.  The washed cells were then lysed using lysis buffer (50 mM tris base, 150 mM NaCl, 1% 
NP40, pH titrated to 7.4 with HCl) for 30mins at 37°C.  The lysate was recovered from each well by 
aspiration using a standard pipette.  The quantity of radio-labeled drug was measured in DPMs using a 
Beckman LS 60001C liquid scintillation counter.  Background signal contributed from non-specific 
binding of drug to the plate surface was subtracted from each measurement.  Dilutions of each 
radiolabeled drug stock were performed to attain a standard curve relating DPMs to nanomoles of drug.  
Measured DPMs in the cell samples were then converted to nanomoles of drug.  Protein abundance was 
measured for each sample using the BCA method.  The calculated nanomoles of drug present in each 
sample was then normalized to mg protein.   
The ion-trapping dependent cellular accumulation of propranolol was determined mathematically by 
subtracting the ion-trapping independent cellular accumulation (nigericin/monensin treated samples) 
from the total cellular accumulation at each indicated time point.  The activity used for all of the drug 
accumulation experiments were as follows: .06µCi/mL for 3H-propranolol or .1µCi/mL 3H-halofantrine.   
 
Drug Release Assay 
 
WT human fibroblasts were grown in plastic 12-well culture plates at a seeding density of 20,000 cells 
per well.  The cells were exposed to either 5µM propranolol (consisting of 4.995µM unlabeled 
propranolol and 5nM of 3H-propranolol at a final activity of .06µCi/mL ) or 5µM halofantrine (consisting 
of 4.995µM unlabeled halofantrine and 5nM 3H-halofantrine at a final activity of .1µCi/mL) for 4 days.  
The media was refreshed every 48hrs to maintain optimal growth conditions.  At the end of this 4 day 
exposure nigericin and monensin were spiked into the extracellular media to a concentration of 10µM 
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and 20µM, respectively.  At the indicated time points the cells were then rapidly washed twice with 4°C 
D-PBS.  The cells were then lysed for 30 min at 37°C using lysis buffer and the lysate was capture by 
aspiration using a standard pipette.  The quantity of tritium-labeled drug (propranolol or halofantrine) 
was measured in disintegrations per minute (DPM) using a Beckman LS 60001C liquid scintillation 
counter.  Background signal contributed from non-specific binding of drug to the plate surface was 
subtracted from each measurement.  Dilutions of each radiolabeled drug stock were performed to attain 
a standard curve relating DPMs to nanomoles of drug.  Measured DPMs in the cell samples were then 
converted to nanomoles of drug.  Protein abundance was measured for each sample using the BCA 
method.  Measured DPMs were then converted to nanomoles of drug and normalized to protein. 
 
Cell imaging 
All cell imaging was performed on a Nikon Eclipse 80i epifluorescence microscope equipped with a 40× 
(1.40 NA) oil immersion SFLOR objective.  All images were acquired on a Hamamatsu ORCA ER digital 
camera.  Images were analyzed using Metamorph software version 7.0 (Universal Imaging) and ImageJ 
software (free online atrsbweb.nih.gov) software. Madin-Derby Canine Kidney (MDCK) cells were grown 
on glass coverslips under the stated growth conditions and durations of exposure.  Following the end of 
the pre-treatment period the cells were cooled to 4°C for 10mins.  The extracellular media was replaced 
with the test condition plus the addition of 25µM rhodamine 123 (R123) and incubated at 4°C for 1hr 
(R123 utake).  The cells were then washed twice with 37°C D-PBS and the extracellular media was 
replaced with the test condition devoid of R123 and incubated for 30mins at 37°C (R123 efflux period).  
At the end of the efflux period the cells were washed twice in 4°C D-PBS.  Fluorescent images were 
taken during each one of these steps as labeled in the figure.  The live cells were mounting onto a glass 
slide and imaged using the appropriate filter sets for R123 fluorescence.  Images were captured under 
identical instrument settings and scaled equally so that a direct comparison of fluorescence intensity 
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and localization could be performed.  Hoechst stain was used as nuclear marker for cells 30mins prior to 
taking all images at 3µg/mL. 
Western blot analysis 
MDCK cells were grown in 12well culture plates at a seeding density of approximately 150,000 cells per 
dish.  Following a 4 day exposure to the presence or absence of α-tocopherol the cells were washed 
twice with 4 degrees C D-PBS.  Cells were then lysed with RIPA buffer (150mM sodium chloride, 1% TX-
100, 0.5% sodium deoxycholate, 0.1% SDS, 50mM tris, pH 8.0, and the protease inhibitors APL & PMSF).  
The protein abundance was then determined by the BCA method.  Protein samples were then mixed 
with Laemmli buffer.  All protein samples (25 µg per lane) were subjected to 12% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) for 120 minutes.  The proteins were then 
transferred to a 0.2 µm pore PVDF membrane (Millipore) using 300 V*hours.  The PVDF membrane was 
then exposed to primary antibody (1:8000 anti-p-glycoprotein, 1:30,000 anti-ß-actin) for two hours, 
washed, and then exposed to secondary antibody (1:4000  goat anti-mouse HRP) for two hours.  
Detection of HRP-conjugated antibody was achieved by chemiluminescence using Western Lightning-
ECL (PerkinElmer) on autoradiograph film.   
Transmission Electron Microscopy 
 
WT human fibroblasts were grown in 175cm2 culture flasks for 6 days with vehicle alone or 5µM 
propranolol.  Media was refreshed every 48 hrs in order to maintain optimal nutrient conditions.  At the 
end of the 6 day time period the cells were removed and fixed using 0.25% glutaraldehyde for 2 hrs at 
room temperature.  Cells were then washed once and stained with osmium tetroxide 2% w/v in D-PBS 
for 1 hour at room temperature.  The cells were washed one time with D-PBS and stained with tannic 
acid 1% for one hour at room temperature.  The cells were then washed with water and stained with 
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uranyl acetate 4% for 30mins at room temperature.  Following one wash step with water the cells were 
washed in progressively higher concentrations of ethanol until the wash reached 100% ethanol.  
Following the ethanol washes the cells were stained with propylene oxide.  Cells were then embedded 
in EPON resin.  All images were taken on an FEI Tecnai F20 XT Field Emission Transmission Electron 
Microscope. 
Sizing of the lysosomal structures was performed manually using the Image J software (freely available 
at http://rsbweb.nih.gov/ij/).   The data obtained from the manual sizing was then normalized to the 
surface area of cytosol present within the analyzed cell slice and then reported as counts per mm2.  
Lysosomes were divided into three distinct categories, primary, secondary, and lipid laden membrane 
whorls, using published descriptions of their structural features as a guide.(Fawcett 1981)  Briefly, small 
dense granules with homogenous contents were considered to be primary lysosomes.  Due to the 
excessive number of primary lysosomes present within each cell slice, the data present in Figure 5.7 B 
for primary lysosomes is representative of one cell slice (n=1) for each condition.  Larger bodies with 
heterogeneous content including undigested material were considered to be secondary lysosomes.  
Larger densely stained bodies with multiple concentric membrane-like whorls were considered to be 
lipid-laden membrane whorls.  Data presented in Figure 5.7 B for secondary lysosomes and membrane 
whorls are representative of ten cell slices (n=10) for each condition. 
Results and Discussion 
α-Tocopherol recovers the steady state volume of lysosomes in lysosomotropic drug-treated cells 
Although many reports have detailed the positive effects that vitamin E can have on recovering 
lysosome dysfunction and reducing the toxicity of lysosomotropic drugs (Honegger, Scuntaro et al. 1995, 
Scuntaro, Kientsch et al. 1996, Shichiri, Kono et al. 2012), very few have focused specifically on how 
these positive effects ultimately influence the steady state volume of lysosomes.  With this in mind, we 
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first sought to validate the notion that the steady state volume of lysosomes could be used as a 
surrogate marker for lysosomes function.  Honeggar and Coworkers have previous shown that 50µM α-
tocopherol is capable of reducing the lysosome dysfunction caused by propranolol and many other 
lysosomotropic drugs (Scuntaro, Kientsch et al. 1996).  Using a similar vitamin E treatment protocol the 
lysosomal volume of cultured human fibroblasts was assessed in the presence or absence of α-
tocopherol (Figure 5.3).  These results indicated that α-tocopherol was capable of recovering the steady 
state volume of lysosomes in cells treated with propranolol or halofantrine in wild-type human 
fibroblasts. 
α-Tocopherol reduces lysosomotropic drug uptake, reduces ion-trapping dependent mechanisms, and 
reduces the abundance of lipid-laden lysosomes 
In order to more thoroughly explore how α-tocopherol might be reducing the toxic effects of 
lysosomotropic drugs we next sought to explore the effects that α-tocopherol had on the cellular 
accumulation of lysosomotropic drugs.  Others have shown that α-tocopherol is capable of reducing the 
cellular accumulation of lysosomotropic drugs but a thorough analysis of how α-tocopherol was 
mediating this effect was not performed.  Many groups have proposed that α-tocopherol reduces the 
hyper accumulation of lipids within drug-treated cells and by virtue of the decreased lipid content the 
cells accumulate less drug (Honegger, Scuntaro et al. 1995, Scuntaro, Kientsch et al. 1996, Agoston, Orsi 
et al. 2003).  To more deeply explore this we first confirmed that α-tocopherol caused a reduction in the 
cellular accumulation of two lysosomotropic drugs propranolol and halofantrine (Figure 5.4).  We then 
more closely examined the way in which α-tocopherol was reducing the cellular accumulation of these 
drugs.  By using nigericin and monensin to dissipate the lysosomal pH gradient, we specifically measured 
the cellular accumulation of drug by ion trapping-dependent (aqueous volume of lysosomes) and ion 
trapping-independent (lipid binding) mechanisms.  Interestingly, we found that the ion trapping-
dependent drug accumulation mechanisms were most affected by α-tocopherol treatments (Figure 5.5).  
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The data in Figure 5.5 shows that the reduction in propranolol uptake is almost entirely due to reduced 
ion trapping-dependent drug accumulation mechanisms.  Due to the slow kinetic release of halofantrine 
from the cells an accurate measurement of the ion trapping-dependent and -independent drug 
accumulation mechanisms was not attainable.  Following the dissipation of the lysosomal pH gradient 
with nigericin and monensin the halofantrine that accumulated due to ion trapping-dependent 
mechanisms begins to partition out of the cells; however, prior to reaching equilibrium, the nigericin and 
monensin begins to cause visible signs of toxicity to the cells.  Measurements of the ion trapping-
dependent drug accumulation of halofantrine would therefore be lower than the actual value as all the 
halofantrine that accumulated by ion trapping-dependent mechanism has not left the cells.  Propranolol 
on the other hand reaches equilibrium after only a few minutes in the presence of nigericin and 
monensin (Figure 5.6 A) compared to halofantrine which requires greater than 2 hours (Figure 5.6 B).   
Once we had established that α-tocopherol was reducing the ion trapping-dependent drug accumulation 
mechanisms we next sought validate these findings using transmission electron microscopy (Figure 5.7).  
These results showed that α-tocopherol causes a significant reduction in the size of secondary 
lysosomes (Figure 5.7 A) while also substantially reducing the abundance of membrane whorls (lipid-
laden lysosomes) (Figure 5.7 B). 
In our consideration of α-tocopherol-mediated reduction in lysosomotropic drug uptake we had also 
envisaged the possibility that α-tocopherol could be modulating the activity or expression of p-
glycoprotein (p-gp).  P-gp has been well established as a promiscuous drug-transporter that is capable of 
capable of reducing the intracellular accumulation of many drugs (Ward, Szewczyk et al. 2013).  
Conditions that increase expression and/or increase activity of p-gp could conceivably reduce the total 
cellular accumulation of drugs.  To test this possibility we examined the expression and activity of p-gp 
in two closely related Madin-Darby canine kidney cells, MDCK WT and MDCK MDR1 (Figure 5.8).  MDCK 
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WT cells do not express p-gp; however, MDCK MDR1 cells have been stably transfected with the gene 
for p-gp and exhibit a detectable expression of this protein under normal growth conditions (Figure 5.8 
A).  The results shown in Figure 5.8 A show that α-tocopherol does not change the expression of p-gp in 
either MDCK WT or MDCK MDR1 cells.  To test potential changes in the activity of p-gp we employed a 
rhodamine 123 (R123) efflux assay.  R123 is a well-established substrate for p-gp and due to its 
fluorescent properties it is easy to analyze in fluorescence microscopy and quantitative microplate 
assays (Mittapalli, Manda et al. 2013).  With this in mind we measured the efficiency of R123 efflux using 
fluorescence microscopy and a quantitative microplate assay using the cellular lysate from an ensemble 
of approximately 500,000 cells.  Included in Figure 5.8 B & C is the known p-gp inhibitor verapamil 
(labeled as +pgp inhibited).  If α-tocopherol inhibited p-gp activity we would expect the R123 signal to 
be similar to that of the verapamil treated (+pgp inhibited) cells.  Conversely, if α-tocopherol enhanced 
the activity of p-gp then we would expect the α-tocopherol treated cells to have a lower R123 signal as 
compared to the untreated cells (labeled as WT or MDR1).  Our results indicated that α-tocopherol did 
not alter the activity of p-gp-mediated efflux of R123 in either the multi-cell experiment (Figure 5.8 B) or 
in the fluorescence microscopy based experiment (Figure 5.8 C). 
α-Tocopherol recovers the steady state volume of lysosomes in LSD cells 
Similar to improving lysosomal-dysfunction in drug-treated cells, vitamin E has also been shown to 
ameliorate many of the functional impairments of lysosomes seen in LSDs (Xu, Liu et al. 2012).  Although 
many of these functional impairments have been shown to improve (e.g., cholesterol transport, vesicle-
mediated transport, and lysosomal catabolism) the effect of α-tocopherol on the steady state volume of 
lysosomes has not been thoroughly examined.  We therefore sought to evaluate the steady state 
volume of lysosomes in LSD cells with or without α-tocopherol treatment.  We have previous 
established that LSD cells possess a significantly greater lysosomal volume compared to wild type cells 
(Figure 5.1).  Although there are many different LSD disease models to be evaluated, we narrowed our 
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evaluations to just NPC diseased cells due to its phenotypic similarity with the lysosomotropic drug-
induced model (Matsuzawa, Yamamoto et al. 1977, Anderson and Borlak 2006).  Our data showed that 
the steady state volume of lysosomes in NPC diseased cells showed a marked time-dependent and 
concentration-dependent reduction in lysosomal volume in the presence of α-tocopherol (Figure 5.9 A & 
B, respectively). 
Structure activity analysis of vitamin E and its ability to recover lysosomal volume 
In order to establish the key structural features of vitamin E that are primarily responsible for its ability 
to exert its positive effects on lysosomes we performed a targeted structure activity relationship.  Many 
groups have postulated mechanisms by which vitamin E can elicit its beneficial effects.  Common among 
these hypotheses is that vitamin E helps to protect cells from free radical lipid peroxidation by virtue of 
its strong antioxidant characteristics (van Acker, Koymans et al. 1993).  The phenolic acid functional 
group present on the heterocyclic ring of vitamin E is responsible for its antioxidant properties allowing 
vitamin E to work as a “chain terminator” which stops the “propagation steps” of free radical damage 
(van Acker, Koymans et al. 1993, Wang and Quinn 1999).  To test the importance of this phenolic acid-
mediated antioxidant property we evaluated several different molecules, all of which possessed 
phenolic acid or poly-phenolic acid functional groups, for their capacity to recover the steady state 
volume of lysosomes in NPC diseased cells (Figure 5.10).  We reasoned that if the antioxidant properties 
of vitamin E were the mechanism by which vitamin E helped to recover lysosomal function then we 
would expect to see a decrease in the steady state volume of lysosomes as measured by LTR uptake.  
The results illustrated in Figure 5.10 indicated that none of these phenolic acid-containing molecules 
reduced the bloated lysosomal volume seen in NPC diseased cells, i.e., they did not reduce the 
lysotracker red uptake below 100% which represents a cell with a full NPC-diseased lysosome.  Due to 
the cytotoxic effects of some of these test compounds depicted in Figure 5.10 we were unable to 
evaluate a 50µM concentration as was done with vitamin E.  However, the compounds there were not 
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toxic up to 100µM (albuterol and rutin) still showed no reduction in the steady state volume of 
lysosomes (data not shown). 
After observing that the phenols and polyphenols were incapable of reducing the bloated lysosomal 
volume of NPC diseased cells, we next sought to assess how changes to the phenolic acid functional 
group on vitamin E itself would influence its ability to recover lysosomal volume (Figure 5.11).  Our data 
indicated that vitamin E, specifically α-tocopherol (Figure 5.11 A) and δ-tocopherol (Figure 5.11 B), was 
capable of reducing the lysosomal volume in NPC diseased cells with or without a free (unconjugated) or 
intact phenolic acid on its heterocyclic ring.  These intriguing results suggested that vitamin E does not 
mediate its beneficial effects to lysosomes by its antioxidant properties. 
Conclusion 
Both LSDs and drug-induced lysosome dysfunction have been observed to cause severe toxic effects 
(Honegger, Scuntaro et al. 1995, Futerman and van Meer 2004, Jeyakumar, Dwek et al. 2005).  LSDs 
represent a category of diseases that present in the human population at a relatively high frequency at 
approximately 1 in 8000 live births.  Unfortunately, many of these LSDs lead to progressive 
neurodegeneration and ultimately death.  There are currently no FDA approved treatments for the brain 
pathologies caused by these diseases (Jeyakumar, Dwek et al. 2005).  LSDs therefore represent a poorly 
served disease in regard to available pharmaceutical interventions.  In addition to the inherited 
acquisition of lysosomal storage diseases, many lysosomotropic drugs have been shown to cause 
perturbations in lysosome function that ultimately give rise to a biochemical and morphological 
phenotype similar to that seen in LSD cells (Matsuzawa, Yamamoto et al. 1977, Anderson and Borlak 
2006).  Although the clinical ramifications of this drug-induced phenotype are currently not known, the 
FDA has considered this off-target drug effect to be highly dubious and has consequently formed a 
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special working group (Phosphoplipidosis Working Group) to examine drug-induced changes to 
lysosomes  (Reasor, Hastings et al. 2006, Tengstrand, Miwa et al. 2010).   
Very recently, vitamin E has shown great promise in its ability to help recover lysosome dysfunction in 
both LSDs and in cells treated with lysosomotropic drugs (Honegger, Scuntaro et al. 1995, Shichiri, Kono 
et al. 2012, Xu, Liu et al. 2012).  In this chapter we have sought to explore how vitamin E helps to 
recover a normal lysosome phenotype in both LSDs and in cells treated with lysosomotropic drugs.  In 
addition, we have also sought to develop a structure activity relationship to explore what structural 
features are important for vitamin E’s ability to recover a normal lysosome phenotype. 
We have shown that the steady state volume of lysosomes in LSDs (Figure 5.1) and in lysosomotropic 
drug-treated cells (Figure 1.2) both exhibit a substantially larger volume compared to their respective 
controls.  We reasoned that the greater lysosomal volume seen in both of these conditions is the 
ultimate manifestation of an amalgam of several different lysosomal impairments and that lysosomal 
volume can therefore be used as a surrogate marker for determining proper lysosome function.  
Following this assumption we measured the steady state volume of lysosomes in the presence or 
absence of vitamin E (α-tocopherol) in both the LSD model, NPC diseased cells (Figure 5.9), and the 
lysosomotropic drug-induced model, propranolol or halofantrine treated cells (Figure 5.3).  In both of 
these models we found that vitamin E was capable of reducing the steady state volume of lysosomes.  
We believe that this indicated that vitamin E was helping to recover proper lysosome function and 
thereby facilitated a recovery of a more normal steady state volume of lysosomes.  Consistent with this 
idea previous reports have shown that this same vitamin E treatment regime, i.e., 50µM α-tocopherol in 
human fibroblasts, was capable of improving the lysosomal impairments caused by LSDs and 
lysosomotropic drug treatments (Honegger, Scuntaro et al. 1995, Shichiri, Kono et al. 2012, Xu, Liu et al. 
2012).   
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Although the precise mechanism for vitamin E-mediated recovery of lysosome function is not currently 
understood, many groups have made an interesting observation in that α-tocopherol treatments tend to 
reduce the intracellular accumulation of lipids in both in vitro and in vivo models (Honegger, Scuntaro et 
al. 1995, Scuntaro, Kientsch et al. 1996, Agoston, Orsi et al. 2003).  As a consequence of this reduced 
lipid content others have postulated that the total cellular accumulation of the offending lysosomotropic 
drug, and its toxic effects, are thereby reduced because of the lower abundance of lipid-binding sites 
(Xu, Liu et al. 2012). 
In previous chapters we detailed that the accumulation of lysosomotropic drugs is due to both ion 
trapping-dependent (aqueous volume of lysosomes) and ion trapping-independent (intracellular protein 
binding, lipid binding, DNA binding etc) mechanisms.  Decreases to either of these components should 
conceivably result in a decrease in the total accumulation of lysosomotropic drugs.  In an effort to more 
thoroughly evaluate the way in which vitamin E (α-tocopherol) was reducing the accumulation of 
lysosomotropic drugs we assessed the changes occurring to both the ion trapping-dependent and ion 
trapping-independent drug accumulation mechanisms (Figure 5.5).  To our knowledge this is the first 
evaluation of this nature.  Interestingly, our results indicated that vitamin E (α-tocopherol) primarily 
reduces the ion trapping-dependent drug accumulation mechanisms for propranolol.  The drug 
accumulation-capacity for the ion trapping-dependent mechanisms should primarily be influenced by 
changes in the total volume of the lysosomal system.  We reasoned that the reduced ion trapping-
dependent drug-accumulation of propranolol seen with the coadministration of α-tocopherol should be 
the result of a decrease in the total number of lysosomes and/or a decrease in the size of the lysosomes.  
To elucidate which one of these changes was occurring we performed a quantitative ultrastructure 
analysis of the lysosomes in wild type human cells receiving 5µM propranolol with or without vitamin E 
(α-tocopherol) (Figure 5.7).  Our results indicated that the size distribution of secondary lysosomes was 
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significantly reduced (Figure 5.7 A) and the abundance of membrane whorls (lipid-laden lysosomes) was 
also substantially decreased (Figure 5.7 B). 
Although vitamin E has shown great promise in resorting lysosome function in both LSD models and in 
the drug-induced model, vitamin E possesses very poor drug-like properties.  Vitamin E has an extremely 
poor water solubility, is highly susceptible to oxidation (Wang and Quinn 1999), and is a substrate for 
liver P450 enzyme metabolism by CYP4F2 (particularly δ-tocopherol) (Xu, Liu et al. 2012).  Vitamin E is 
therefore unlikely to ever become a viable treatment for either of these two conditions.  With this in 
mind we have performed a targeted structure activity relationship of vitamin E (α-tocopherol and δ-
tocopherol) in an attempt to identify the primary structural feature that is responsible for vitamin E’s 
ability to restore lysosome function.  Others have postulated that vitamin E elicits its positive effects 
primarily through its antioxidant properties that mitigate the cellular damage caused by lipid 
peroxidation (van Acker, Koymans et al. 1993).  The antioxidant properties of vitamin E have been well 
characterized and have been attributed to the phenolic acid functional group present on its heterocyclic 
ring (van Acker, Koymans et al. 1993, Wang and Quinn 1999).  With this in mind we tested a battery of 
many different phenol and polyphenol-containing molecules for their ability to restore a normal 
lysosome volume in NPC diseased cells (Figure 5.10).  The results illustrated in Figure 5.10 indicated that 
the antioxidant properties of phenolic acids alone is not capable of restoring a normal lysosomal volume 
in NPC diseased cells.   
From these results we had reasoned that intercalation into membrane was likely playing an important 
functional role in vitamin E’s ability to restore lysosome function, and by extension reduce the bloated 
lysosomal volume of the diseased cells.  Consistent with this idea others have postulated that vitamin E 
exerts its beneficial effects by influencing membrane dynamics such as membrane fluidity and order 
(Wang and Quinn 1999).  To more thoroughly dissect the importance of the antioxidant properties 
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versus the influence on membrane dynamics, we analyzed a battery of vitamin E analogs that all 
contained various functional changes to the phenolic acid group (Figure 5.11).  Interestingly, we found 
that the phenolic acid functional group was not responsible for these molecules ability to restore 
lysosomal volume in NPC diseased cells.  Although a more thorough evaluation of membrane dynamics 
is in order, these results support the notion that vitamin E improves lysosome function primarily through 
its ability to influence membrane dynamics rather than its ability to function as an antioxidant. 
In this chapter we have explored the effect that vitamin E has on the steady state volume of lysosomes 
in NPC diseased cells and in wild type cells treated with lysosomotropic drugs.  We have shown that 
vitamin E reduces the bloated lysosomal volume seen in both of these conditions.  In addition we have 
also provided the foundation for a structure activity relationship that highlights the importance of 
vitamin E’s membrane interactions rather than its antioxidant properties.  Although further studies are 
required to more thoroughly characterize how vitamin E is influencing lysosomal membrane dynamics, 
this chapter provides a proof of principle showing that it can be possible to rationally design drugs that 
could potentially be used to treat lysosomal storage disorders or the toxic effects of lysosomotropic 
drugs. 
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Figure 5.1  Assessments of the steady-state volume of lysosomes in multiple human fibroblast cell lines.  
Wild-type represents non-diseased cells while Niemann-Pick Type C1 (NPC1-/-), Niemann-Pick Type C2 
(NPC2-/-), Niemann-Pick Type A (NPCA), and Sandhoff Diseased (Sandhoff) cells represent cell lines that 
all exhibit dysfunctional lysosomes.  The reported values represent the average of approximately 
500,000 cells measured by a minimum of three independent experiments.  The cellular accumulation of 
lysotracker red (LTR) was measured in fluorescence units and then normalized to cellular protein.  The 
normalized LTR uptake was then compared to the wild-type condition and reported as a percentage of 
the wild-type.  
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Figure 5.2  The molecular structures of the 8 isoforms of vitamin E. 
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Figure 5.3  Assessments of the steady-state volume of lysosomes in wild-type human fibroblasts pre-
treated for 48hrs under various conditions, as stated in the figure.  The graph illustrates the cellular 
uptake of lysotracker red (LTR).  The reported values represent the average of approximately 500,000 
cells measured by a minimum of three independent experiments.  The cellular accumulation of 
lysotracker red (LTR) was measured in fluorescence units and then normalized to cellular protein.  The 
normalized LTR uptake was then compared to the vehicle-treated control and reported as a percentage 
of control.  
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Figure 5.4  Total cellular accumulation of (A) propranolol or (B) halofantrine in the presence or absence 
of 50µM α-tocopherol (as indicated in the figure).  Cells were exposed to the indicated condition over a 
6 day period prior to analizing the cellular accumulation of the drug.  The cellular accumulation of drug 
was measured using tritrium-labeled drugs at an activity of .06µCi/mL (propranolol) or .1µCi/mL 
(halofantrine) and then reported as nanomoles of drug.  The nanomoles of drug were then normalized 
to the cellular protein present within the sample.  
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Figure 5.5  Cellular accumulation of propranolol by ion trapping-depenedent and ion trapping-
indpendent drug accumulation mechanisms (as indicated in the figure) after a 6 day treatment with or 
without the coadministration of α-tocopherol.  The ion trapping-independent values were obtained by 
measuring the cellular accumulation of propranolol in the absence of a lysosomal pH gradient (nigericin 
and monensin treated).  The ion trapping-dependent values were obtained mathematically by 
subtracting the ion trapping-independent value from the total cellular accumulation of propranolol with 
an intact lysosomal pH gradient (normal growth conditions).  The cellular accumulation of drug was 
measured using tritrium-labeled drugs at an activity of .06µCi/mL (propranolol) or .1µCi/mL 
(halofantrine) and then reported as nanomoles of drug.  The nanomoles of drug were then normalized 
to the cellular protein present within the sample.   
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Figure 5.6  The washout kinetics of ion trapping-dependent drug (A) propranolol or (B) halofantrine from 
cells after a 4 day 5 micromolar drug-uptake period in wild-type human fibroblasts.  Following the 4 day 
uptake period nigericin and monensin was spiked into the exsisting cell culture media and then 
incubated for the times indicated on the graph.  The amount of drug remaining in the cells was then 
plotted as a function of time.  The cellular accumulation of drug was measured using tritrium-labeled 
drugs at an activity of .06µCi/mL (propranolol) or .1µCi/mL (halofantrine) and then reported as either 
nanomoles of drug or decays per minute (dpm).  The abundance of drug was then normalized to the 
cellular protein present within the sample. 
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Figure 5.7  Quantitative ultrastructure analysis of lysosomes in wild-type human fibroblasts treated with 
5µM propranolol with or without 50µM α-tocopherol for a 6 day period.  Lysosomes were designated as 
either (A) secondary lysosomes or (B) membrane whorls and then manually sized using Image J (a 
software freely available at chemaxon.com).  The size distribution and frequency of occurace (avg count 
per cell) was then depicted as a histogram.  The values illustrated in the graphs are measurments from 
10 independent cells. 
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Figure 5.8 Cellular abundance and activity of of p-glycoprotein (p-gp) in Madin-Darby canine kidney 
(MDCK) cells.  (A) Westernblot analysis of the cellular abundance of p-gp in MDCK wild-type (WT) that 
do not express p-gp and MDCK MDR1 that have been stabily transfected with the gene for p-gp.  Both 
cell lines were exposed to vehicle (control) or 50µM α-tocopherol (50µM Vit E) for a 6 day period prior 
to westernblot analysis.  The activity of p-gp was assessed by measuring the cellular accumulation of the 
p-gp substrate rhodamine 123 (R123) using a (B) quantitative microplate assay of approximately 750,000 
cells or (C) fluorescence microscopy approximately 6-12 cells.  In both (B) and (C) cells were grown in the 
presence or absence of 50µM α-tocopherol for 6 days.  The cells were then exposed to R123 for a 1hr 
period followed by a 30minute R123 wash-out period.  The remaining R123 that was present within the 
cells was measured in relative fluorescence units (RFU) and normalized to the abundance of cellular 
protein.  As a positive control for altered p-gp activity the control condition was duplicated; however, 
during the R123 uptake and release period 100µM verapamil (a known p-gp inhibitor) was added to the 
exsisting cell culture media.  
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Figure 5.9  Assessments of the (A) time-dependent and (B) concentration-dependent affects that vitamin 
E (α-tocopherol) on the steady-state volume of lysosomes in Niemann-Pick Type C (NPC) diseased 
human fibroblasts.  (A) NPC diseased cells were exposed to 50µM α-tocopherol for the indicated 
exposure time.  The lysosomal volume was measured by lysotracker red (LTR) uptake in relative 
fluorescence units (RFUs) and then normalized the abundance of cellular protein.  (B)  NPC diseased cells 
were grown for 6 days in the absence (control) or presence of various concentrations of α-tocopherol.  
The lysosomal volume was measured by lysotracker red (LTR) uptake in relative fluorescence units 
(RFUs) and then normalized the abundance of cellular protein.  In (A) the RFUs per µg protein were 
compared to the values for NPC diseased cells grown in α-tocopherol-free media (control) and then 
depicted as a percent of control.  The data illustrated in (A) and (B) are representative of a minium of 3 
independent experiments.  
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Figure 5.10  Assessments of the steady-state volume of lysosomes of Niemann-Pick Type C (NPC) 
diseased cells in the presence or absence of various phenol and poly-phenol containing molecules.  NPC 
diseased cells were exposed to 10µM of each of the indicated compounds for a 4 day time period.  At 
the end of the 4 day exposure to the test compounds the cellular uptake of lysotracker red (LTR) was 
measured in fluorescence units (RFUs) and then normalized to the abundance of cellular protein.  These 
values were then compared to NPC diseased cells with no test compound (control) and depicted as a 
percent of control.  The data illustrated in this figure are representative of a minium of 3 independent 
experiments.  
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Figure 5.11 Assessments of the steady-state volume of lysosomes of Niemann-Pick Type C (NPC) 
diseased cells in the presence or absence of vitamin E and vitamin E derivatives.  NPC diseased cells 
were exposed to 50µM of each of the indicated compounds for a 4 day time period.  At the end of the 4 
day exposure to the test compounds the cellular uptake of lysotracker red (LTR) was measured in 
fluorescence units (RFUs) and then normalized to the abundance of cellular protein.  These values were 
then compared to NPC diseased cells with no test compound (control) and depicted as a percent of 
control.  The data illustrated in (A) and (B) are representative of a minium of 3 independent 
experiments.  
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Chapter 6. Conclusions 
Summary and Conclusion 
In this work we have detailed how lysosomotropic drugs can alter lysosome form and function and 
cause an expanded lysosomal volume phenotype (expanded LVP).  This phenotype was characterized by 
an increase in the aqueous volume of lysosomes that consequently lead to the enhanced cellular 
accumulation of lysosomotropic drugs.  Although lysosomotropic drugs have previously been shown to 
enhance the cellular accumulation of secondarily administered drugs, and thereby create a drug-drug 
interaction involving lysosomes, a mechanistic basis for this phenomenon has not been established.  The 
purpose of this work was to fill the gap in knowledge regarding the details of the expanded LVP; 
specifically, the structure activity relationship for molecules and their ability to induce an expanded LVP, 
the mechanism underlying their effect on lysosomes, and what cellular processes are involved in its 
development. 
In an effort to establish a structure activity relationship, we have evaluated a wide array of 
lysosomotropic molecules and examined the influence that specific physicochemical properties had on 
their ability to induce an expanded LVP.  We found that lysosomotropic properties greatly enhanced a 
molecule’s capacity to increase lysosomal volume.  Our data further showed that the amphiphilic 
properties of lysosomotropic molecules, e.g., the size of the hydrophobic region and the distance 
separating it from the hydrophilic region, dramatically influenced their potency to induce an expanded 
LVP. 
We then explored the mechanisms underlying how these structural properties might be leading to an 
expanded LVP.  We had reasoned that the amphiphilic properties of these molecules were important 
because it was determined how they were interacting with the biological membranes.  To test this this 
we quantitatively measured the membrane intercalation potential (drug-induced red blood cell 
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hemolysis) of several different lysosomotropic molecules.  Interestingly, we found that the membrane 
intercalation potential of 5 different lysosomotropic drugs correlated strongly with their relative 
potency in causing an expanded LVP.  To strengthen this hypothesis we further showed that low 
concentrations of lysosomotropic drugs could work in an additive manner to ultimately bring about an 
expanded LVP similar to that seen with a single drug at a higher concentration.  We deemed these 
findings to be further evidence that these lysosomotropic drugs were interacting with the lysosomal 
membranes and that this interaction was causing a non-specific effect such as changing membrane 
fluidity and order. 
Following the development of the structure activity relationship and implicating membrane intercalation 
as a likely mechanism underlying the initial effects of these drugs, we next sought to characterize the 
down-stream consequences of these interactions.  We did not consider the membrane intercalation of 
lysosomotropic drugs to be the direct cause of the expanded LVP; rather, we envisaged that it was 
initiating some unidentified downstream cellular response.  Due to the vast complexity of biological 
systems, we could not screen every cellular process for its potential involvement in this drug-induced 
phenomenon.  Instead, we imaged a simplified model of the lysosomes where its steady state volume 
would be determined by the relative balance between pathways that bring membrane and material into 
the lysosomal systems compared to pathways that bring membrane and material away from the 
lysosomal system.  We then evaluated the role that two well characterized input pathways, the 
autophagic pathway and the biosynthetic pathway, played in expanding lysosomal volume.  Our results 
showed that cells exposed to lysosomotropic drugs exhibit increased levels of autophagy and 
biosynthesis of lysosomes (via transcription factor EB (TFEB) activation).  We also evaluated the effect 
that lysosomotropic drugs had on vesicle-mediated trafficking away from lysosomes.  We found that 
these in addition to enhancing the rate of input into the lysomal system these drugs were also 
decreasing the efficacy of vesicle-mediated trafficking out of the lysosomes.  We concluded that these 
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two down-stream effects, i.e., increased rates of input into the lysosomal system and decreased rates of 
egress from the lysosomal system, ultimately lead to an increase in the steady state volume of 
lysosomes. 
In continuation of the work by Funk and Krise, we next sought to evaluate the potential clinical 
ramifications of the expanded LVP by determining how this condition could impact the cellular 
accumulation of lysosomotropic drugs.  We had reasoned that if these drugs were capable of altering 
the cellular accumulation of secondarily administered drugs then this phenomenon could ultimately 
instigate a drug-drug interaction involving lysosomes.  Funk and Krise previously identified this drug-
drug interaction pathway by reporting that the lysosomotropic drugs could enhance the cellular 
accumulation of lysotracker red (LTR).  Because LTR is technically not a drug, we sought to re-evaluate 
this drug-drug interaction using more clinically relevant examples.  In these assessments we addressed 
two important questions.  First, can these lysosomotropic drugs increase their own cellular 
accumulation.  And finally, can these lysosomotropic drugs cause an enhanced cellular accumulation of 
secondarily administered drugs. 
Our results showed that the drug-induced expansion of lysosomal volume caused an increased cellular 
accumulation of the primary lysosomotropic drug, i.e., one lysosomotropic drug can increase its own 
cellular accumulation.  We also found that the drug-induced expansion in lysosomal volume could also 
increase the cellular accumulation of secondarily administered drugs. 
In the final chapter we explored potential treatment strategies for recovering lysosome function in 
lysosomal storage diseased (LSD) cells and in cells treated with lysosomotropic drugs.  Inspired by 
previous reports showing the positive effects that vitamin E can have on improving lysosome-
dysfunction we sought to further evaluate vitamin E and attempt to determine the important structural 
features of these molecules.  By analyzing a battery of vitamin E analogs (α-tocopherol and δ-
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tocopherol) and a group of compounds containing phenols and polyphenols we found that the 
antioxidant properties of vitamin E were not responsible for its ability to recover lysosome function in 
Niemann-Pick Type C (NPC) diseased cells.  We concluded that the positive effects of vitamin E were 
likely due to beneficial membrane interactions that counteracted the impingement induced by 
lysosomotropic drugs or the build-up of undegraded substrates in LSDs cells.  Although further studies 
are required to more thoroughly characterize how vitamin E is influencing lysosomal-membrane 
dynamics this chapter provides a proof of principle showing that it can be possible to rationally design 
drugs that could potentially be used to treat lysosomal storage diseases or the toxic effects of 
lysosomotropic drugs. 
Future Work 
The discovery process initially starts with a simple model and then expands to include increasingly more 
complex models.  Throughout this work we have focused our studies on cells in culture.  These studies 
represent only the beginning stage of discovery.  We have used an in vitro model to develop our 
hypotheses on how many lysosomotropic drugs might be influencing and changing lysosomes.  Based on 
these results we have made predictions on how these drug-induced changes could ultimately impact the 
pharmacokinetic properties of drugs in a clinical setting.  Although we feel that our hypotheses and 
conclusions are well reasoned they are ultimately based on an in vitro model.  The next stage in the 
discovery process is to apply what was learned in this work and expand it to an in vivo model. 
